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Abstract
Memory deficits are recognized in Parkinson’s disease (PD). The nature of these memory deficits
is unclear because few studies have both isolated memory encoding and retrieval processes while
testing patients on and off their dopamine replacement medication. Previous work suggests
encoding depends upon regions innervated by the ventral tegmental area, which is relatively spared
in PD, while retrieval depends upon dorsal striatum, which is dopamine deficient even early in PD.
We investigated the impact of a dopamine transporter (DAT1), a dopamine reuptake protein,
polymorphism (a 40-base-pair variable repeat affecting expression) on encoding and retrieval in
healthy, elderly controls as well as in patients on and off medication. We only found encoding
deficits in PD patients who carry a DAT1 polymorphism when on, relative to off, medication,
suggesting interactive effects of medication and genotype. We found improvements in memory
retrieval in patients who were on, relative to off, medication, but this effect may be independent
of DAT1 genotype. This work demonstrates the need for further investigation of interactive effects
of medication and genetic profile in PD.

Keywords

i

Parkinson’s disease, polymorphism, dopamine transporter, dorsal striatum, ventral striatum,
memory encoding, memory retrieval.

ii

Co-Authorship Statement
I completed all aspects of the following experiment, but received assistance with data
collection from Ken Seergobin, Alex MacDonald, Abdullah Al Jaja, Marissa Burns, and Connor
Lewicki. Additionally, all genotyping work was completed in the lab of Dr. Richard Kim. Ken
Seergobin and Dr. Penny MacDonald also assisted with data processing and analysis. I prepared
the manuscript myself, which was edited by Dr. Penny MacDonald. This experiment was
completed at Sudbury Regional Hospital and the Brain and Mind Institute, located at the University
of Western Ontario.

iii

Acknowledgments
I would like to express my sincere gratitude to the following people, all of whom contributed to a
fantastic experience as a student in the MacDonald Lab.


Dr. Penny MacDonald for her tireless efforts to ensure I have the most enriching
experience possible, for placing so much trust in me, and for supporting me
wholeheartedly. I could not have asked for a better supervisor.



Dr. Adrian Owen for his support and guidance throughout my experience at the BMI.



Nole Hiebert for being my first-line support and oracle of knowledge since I was a lowly
undergraduate thesis student.



Andrew Vo for all the dry humour and insights.



Daniel Glizer for the endless positivity and good vibes.



Kate Merritt for not forgetting about us while she’s way up there on the second floor.



Alex MacDonald for laughter and moral support.



Ken Seergobin for all the technical expertise and patience.



The Kim lab for their assistance with our genetic analyses.



My family for all their love and support along the way.

This work was supported by start-up funds and an Opportunity Grant from the Academic
Medical Organization of Southwestern Ontario awarded to Dr. Penny MacDonald, and a Canada
Excellence Research Chair (CERC) award to Dr. Adrian Owen.

iv

Table of Contents
Abstract ................................................................................................................................. i
Co-Authorship Statement ..................................................................................................... iii
Acknowledgments ................................................................................................................ iv
Table of Contents .................................................................................................................. v
List of Tables ....................................................................................................................... vii
List of Figures ......................................................................................................................viii
List of Appendices ................................................................................................................ ix
List of Abbreviations .............................................................................................................. x
1.0 Literature Review ............................................................................................................ 1
1.1 Motor Symptoms in Parkinson’s Disease ...................................................................................1
1.2 Basal Ganglia ............................................................................................................................1
1.3 Pathophysiology of Motor Symptoms in PD ..............................................................................4
1.4 Cognitive Symptoms in PD ........................................................................................................5
1.4.2 Dopamine Overdose Hypothesis ................................................................................................. 9
1.5 Memory Impairments in PD .................................................................................................... 11
1.6 Memory ................................................................................................................................. 11
1.6.1 Memory encoding ..................................................................................................................... 12
1.6.2 Memory Retrieval...................................................................................................................... 15
1.7 Memory Encoding and Retrieval in PD .................................................................................... 18
1.8 Influence of Genotype on Encoding and Retrieval .................................................................... 26
1.8.1 DAT1 .......................................................................................................................................... 26
1.8.2 DAT1 Genotype and Cognition .................................................................................................. 27
1.9 Aims of the Present Study....................................................................................................... 31
1.10 Hypotheses/Predictions ........................................................................................................ 31

2.0 Methods ........................................................................................................................ 32
2.1 Participants ............................................................................................................................ 32
2.2 Genotyping Procedure and Results ......................................................................................... 35
2.3 Design and Procedure ............................................................................................................. 36
2.4 Data Analysis ......................................................................................................................... 37

3.0 Results........................................................................................................................... 39
3.1 Encoding Phase ...................................................................................................................... 39
3.2 Recall Phase ........................................................................................................................... 42

4.0 Discussion...................................................................................................................... 43
4.1 Summary of Results ................................................................................................................ 43
4.2 Memory Encoding and Retrieval in PD .................................................................................... 44
4.3 Interpretation of Memory Encoding Results ............................................................................ 45
4.4 Interpretation of Memory Retrieval Results ............................................................................ 49
4.5 Relevance of Current Study to Memory Function in PD ............................................................ 52
4.6 DAT1 Effects on Memory Function in PD ................................................................................. 52

v

4.6.1 Encoding Effects ........................................................................................................................ 53
4.6.2 Retrieval Effects......................................................................................................................... 57
4.7 Limitations of the Current Study ............................................................................................. 58
4.8 Conclusion ............................................................................................................................. 59
4.9 References ............................................................................................................................. 61

6.0 Curriculum Vitae ............................................................................................................ 96

vi

List of Tables
Table 2.1: Demographic and screening data for PD patients and controls separated by
genotype ............................................................................................................................. 34
Table 3.1: Final study-immediate recall, encoding scores, and weighted recall scores for PD
patients and controls separated by DAT1 genotype ............................................................. 41

vii

List of Figures
Figure 1.1: Basal Ganglia-Thalamocortical Loops .................................................................... 4
Figure 1.2. Inverted-U function of dopamine levels and performance. .................................. 10
Figure 1.3. Percentage of verbally-presented items successfully recalled after 30-minute and
24-hour delays .................................................................................................................... 22
Figure 3.1. Learning Scores .................................................................................................. 42
Figure 3.2. Recall Scores ...................................................................................................... 43

viii

List of Appendices
5.1 List A symbols used on Day 1 of testing. ......................................................................... 90
5.2 List B symbols used on Day 1 of testing. ......................................................................... 91
5.3 List A symbols used on Day 2 of testing. ......................................................................... 92
5.4 List B symbols used on Day 2 of testing. ......................................................................... 93
5.5 Ethics approval notice from the Sudbury Regional Hospital ............................................ 94
5.6 Ethics approval from the University of Western Ontario ................................................. 95

ix

List of Abbreviations

9R

9-repeat allele

10R

10-repeat allele

AComm

Anterior communicating artery

AFLT

Aggie Figures Learning Test

ANART IQ

National Adult Reading Test IQ estimation

ANOVA

Analysis of variance

BAI

Beck Anxiety Inventory

BDI-II

Beck Depression Inventory

cAMP

Cyclic adenosine monophosphate

DAT1

Dopamine transporter

DS

Dorsal striatum

dlPFC

Dorsolateral prefrontal cortex

fMRI

Functional magnetic resonance imaging

L-dopa

l-3,4-dihydroxyphenylalanine

LED

Levodopa equivalent dose

MOCA

Montreal Cognitive Assessment

MSN

Medium spiny neuron

OFC

Orbital frontal cortex

PD

Parkinson’s disease

PET

Positron emission tomography

PFC

Prefrontal cortex

x

PKA

Protein kinase A

RAH

Recurrent artery of Heubner

RAVLT

Rey Auditory Visual Learning Test

SAS

Starkstein Apathy Test

SEM

Standard error of the mean

SN

Substantia nigra

UPDRS

Unified Parkinson’s Disease Rating Scale

VNTR

Variable nucleotide tandem repeat

VS

Ventral striatum

VTA

Ventral tegmental area

xi

1
1.0 Literature Review
1.1 Motor Symptoms in Parkinson’s Disease
Parkinson’s disease (PD) is a common neurodegenerative disorder that affects 173 of every
100,000 55-64 year olds worldwide, with increasing prevalence later in life (Pringsheim et al.,
2014). PD is characterized by the motor symptoms of slowness of movement (i.e., bradykinesia),
increased muscular tone (i.e., rigidity), and resting tremor. These symptoms occur due to
degeneration of dopamine-producing neurons in the substantia nigra (SN), a midbrain region
belonging to the basal ganglia. When ~70% of these neurons degenerate, the SN’s primary efferent
region, the dorsal aspect of the striatum (DS), becomes sufficiently dopamine depleted, causing
motor symptoms to arise (Kish et al., 1988). The striatum is the input region of the basal ganglia,
as detailed below.

1.2 Basal Ganglia
The basal ganglia are a collection of subcortical nuclei implicated in motor control and,
increasingly, in cognitive function (Cools, 2006; Grahn et al., 2008; MacDonald and Monchi,
2011). These nuclei consist of the striatum, SN, globus pallidus, and subthalamic nucleus (Kandel
et al., 2013). The striatum, the input structure to the basal ganglia, can be anatomically divided
into the caudate nucleus and putamen (Kandel et al., 2013). It receives glutamatergic afferents
from the thalamus and all cortical regions, save the primary visual and auditory cortices (Alexander
et al., 1986). The SN supplies dopamine almost exclusively to the bulk of the caudate nucleus and
putamen, which together form the DS. The VTA supplies dopamine to the most ventral aspects of
the caudate and putamen, as well as to the nucleus accumbens, which together constitute the VS.
The ventral tegmental area (VTA) also provides dopaminergic innervation to frontal cortical
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regions, and limbic cortices, including hippocampus and amygdala (Cools, 2006; MacDonald &
Monchi, 2011).

Though at a gross level of inspection the caudate and putamen appear to be separate structures, at
a microscopic level these regions cannot be discriminated (David, et al., 2005; Iversen and
Dunnett, 1990). Further, although sub-regions of both caudate and putamen differ in the cortical
inputs they receive, even these are somewhat overlapping (Choi, et al., 2012; Draganski, et al.,
2008; Lehéricy, et al., 2004; Postuma & Dagher, 2006) as is their dopamine supply. In line with
this, despite claims that the caudate and putamen are functionally separate (Balleine, et al., 2009;
Ashby et al., 2007; Jessup and O'Doherty, 2011), these distinctions do not hold up upon closer
inspection of the literature. The operations implicating these brain regions are in fact quite
corresponding (Grahn et al., 2008; Burgaleta, et al., 2014; DeGutis and D’Esposito, 2007; Jiang,
et al., 2015; Jueptner, et al., 1997; Kimura, 1992; Lam, et al., 2016; Monchi, et al., 2001; Samejima,
et al., 2005; Foerde, et al., 2013; Lehericy, et al., 2005). Consequently, at this time, there is
insufficient evidence that caudate and putamen are distinct operationally, rationalizing our strategy
of referring to caudate and putamen as DS. In contrast, distinctions between VS and DS are
justified by distinct histological features that adapt them to different functions and based on
entirely non-overlapping reciprocal cortical afferents as well as different dopamine supplies
(Kincaid, et al., 1998; Leh, et al., 2007; Voorn, et al., 2004; Wickens, et al., 2007). Finally, VS
and DS functions are quite dissimilar (MacDonald and Monchi, 2011).

Medium spiny neurons (MSNs) are the main cell type in the striatum. MSNs are gammaaminobutyric acid-ergic and can be divided into two separate types. The direct pathway contains
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MSNs that predominately express D1 dopamine receptors and project directly to the internal
globus pallidus/SN pars reticulata. The indirect pathway contains MSNs that predominately
express D2 dopamine receptors and project to the external globus pallidus, which is in turn
connected to the internal globus pallidus/SN pars reticulata either directly or through the
subthalamic nucleus (Kandel et al., 2013). Both pathways project from the internal globus pallidus
to regions of the thalamus. The thalamus then projects back to the cortex (Kandel et al., 2013;
Figure 1), with different cortical regions receiving efferents from the striatal regions to which they
initially projected, forming reciprocal connections (Alexander et al., 1986; Postuma and Dagher,
2006). D1 receptor-expressing MSNs of the direct pathway are coupled to a G-protein coupled
second messenger system through G(s/olf), which activates adenylyl cyclase, resulting in increased
cyclic adenosine monophosphate (cAMP) production and protein kinase A (PKA) activity
(Beaulieu et al., 2011). Therefore, the presence of dopamine leads to increased activity in direct
pathway MSNs, which causes disinhibition of the thalamus through the internal globus pallidus
(Kandel et al., 2013). D2 receptor-expressing MSNs of the indirect pathway are coupled to G(i/o)
and lead to decreased PKA activity (Beaulieu et al., 2011). The presence of dopamine leads to
disinhibition of the subthalamic nucleus. The subthalamic nucleus then releases more glutamate
onto the internal globus pallidus, leading to inhibition of corresponding thalamic neurons. In
addition, the external globus pallidus also sends projections directly to the internal globus pallidus.
Dopaminergic activity in the striatum modulates synaptic activity and helps maintain a balance
between direct and indirect pathway activity (Kandel et al., 2013). In this way, the net effect of
dopamine is increased cortical activity through activation of direct pathway and depression of the
indirect pathway. Alterations to dopaminergic activity in the striatum, as seen in Parkinson’s
disease (PD), leads to a variety of motor and non-motor symptoms.
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Figure 1.1: Basal Ganglia-Thalamocortical Loops. Cortical input to the basal ganglia is received
by the striatum (here only showing putamen). This information may then travel down the direct
(monosynaptic) or indirect (polysynaptic) pathways before reaching the internal globus pallidus
(GPi). GPi projects onto the thalamus to reroute processed information back to the cortical regions
that provided the initial input to the striatum. Excitatory synapses are shown in red. Inhibitory
synapses are shown in grey. Figure reproduced from Kandel et al., 2013.

1.3 Pathophysiology of Motor Symptoms in PD
The motor symptoms of PD result from decreased direct pathway signaling and increased indirect
pathway signaling in the cortico-basal ganglia-thalamocortical motor circuit (Kandel et al., 2013),
both related to dopamine depletion. This imbalance results in increased activity of the internal
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globus pallidus which causes inhibition of the thalamus and its target regions of the motor cortex.
This in turn produces the cardinal motor symptoms of PD.

As would be expected based on the pathophysiological basis for movement abnormalities,
dopamine replacement therapy is an effective treatment for motor symptoms at all stages of PD.
Dopamine precursors such as l-3,4-dihydroxyphenylalanine (L-dopa) are most commonly used.
L-dopa is often formulated to include a dopamine decarboxylase inhibitor that prevents the
conversion of L-dopa to dopamine in the peripheral circulation, resulting in fewer side effects and
higher concentrations of dopamine in the brain. Dopamine agonists, which are drugs that are
similar in structure to dopamine, may also be used. These drugs are not converted to dopamine,
but rather interact with dopamine receptors in their current state, mimicking the effect of dopamine.

1.4 Cognitive Symptoms in PD
The non-motor symptoms of PD lead to decreased quality of life (Barone et al., 2009; Schrag et
al., 2000) and significant disability (Aarsland et al., 2003, 2009; Verbaan et al., 2007). Over time,
it has become apparent that cognitive symptoms are prominent in PD, especially at later stages of
disease (Muslimovic et al., 2007; Owen et al., 1992). 20-50% of patients eventually manifest
dementia (Bosboom et al., 2004; Caballol et al., 2007; Owen, 2004) and a greater percentage
demonstrate milder cognitive deficits (Aarsland et al., 2003, 2009; Litvan et al., 2011). In nondemented PD patients with milder cognitive impairment, learning functions in particular seem
intact whereas cognitive flexibility (i.e., the ability to alter response strategies to match changing
environments or to shift attention among stimuli) is impaired (Cools, 2006; MacDonald and
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Monchi., 2011). At later stages, cognitive deficits become more pronounced and varied, with a
complete list far from defined.

1.4.1Pathophysiology of Cognitive Symptoms in PD
Unlike the relatively straightforward pathophysiology of motor symptoms, the etiology of
cognitive impairments in PD appears more complex. Whereas some cognitive abnormalities result
from cortical degeneration, which occurs particularly at later stages in PD (Pereira et al., 2012),
other pathological changes almost certainly contribute to abnormal cognition in PD. For example,
there is evidence that some cognitive deficits are attributable to degeneration of neurotransmitter
systems, in addition to dopamine, such as acetylcholine and serotonin (Calabresi et al., 2006;
Scatton et al., 1983). Studies have repeatedly failed to demonstrate correlation between severity of
cognitive impairment and cortical dispersion of abnormal deposits of alpha-synuclein that form
Lewy bodies (Jellinger, 2008; Parkkinen et al., 2005, 2008). Using convergent methodologies, a
growing number of studies now clearly support a role for the striatum in cognition and
dopaminergic abnormalities in striatum are suggested as central mechanisms for cognitive
abnormalities in PD, especially in PD patients with milder cognitive impairment and at earlier
stages of disease (Aarsland et al., 2009; Cools, 2006; Cools et al., 2001, 2003; Frank et al., 2004;
Grahn et al., 2008; Hayes et al., 1998; Hood et al., 2007; MacDonald and Monchi, 2011; Owen et
al., 1992; Shook et al., 2005).

Reviewing cognitive functions ascribed to the striatum initially reveals a diverse and almost
confusing array. Increasingly, it is understood that this apparent miscellany owes to regional
functional specificity within the striatum. Dorsal and ventral portions of striatum are characterized
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by subtle cytoarchitectural differences as well as non-overlapping cortical and dopaminergic
afferents (Wickens et al., 2007; Zhang et al., 2009; Cowan and Wilson, 1994; Kincaid et al., 1998).
By partitioning cognitive functions attributed to DS and VS, two more cohesive sets of cognitive
operations are emerging. The DS is linked to executive functions such as flexibly switching
response strategies and shifting attention whereas the VS seems particularly implicated in learning
(Atallah et al., 2007; Benke et al., 2003; Cameron et al., 2010; Cools, 2006; Cools and D’Esposito,
2011; Cools et al., 2003, 2011; Ell et al., 2006; Grahn et al., 2008; Hiebert et al., 2014; Leber et
al., 2008; MacDonald and Monchi, 2011; MacDonald et al., 2011; Robertson et al., 2015; Shohamy
et al., 2006; Yehene et al., 2008).

In addition to being implicated in different cognitive functions, sources of dopamine for DS and
VS are distinct and degenerate at different times and to varying degrees in PD (Kish et al., 1988).
Unlike the SN, which is significantly degenerated at the time of diagnosis, the dopamine-producing
cells of the VTA are relatively spared in early PD (Kish et al., 1988). The result is that the SNinnervated DS is severely dopamine-depleted and its functions are impaired. In contrast, the brain
regions supplied by the VTA, namely the VS, prefrontal cortex (PFC), and limbic cortices,
including hippocampus, are relatively dopamine replete and their cognitive functions are preserved
(Cools, 2006; MacDonald & Monchi, 2011). In this way, awareness that DS and VS mediate
separate cognitive processes and that SN and VTA degenerate differentially, has yielded a
framework for understanding cognitive dysfunction in PD, particularly prior to late disease stages.

In contrast to motor symptoms that are uniformly improved by dopaminergic therapy in PD,
cognitive functions are dissimilarly affected by dopamine replacement therapy. Some cognitive
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functions are ameliorated or redressed, whereas others are worsened by dopaminergic medication.
There is now an ample literature suggesting that cognitive functions that depend upon DS, or
cortical regions reciprocally connected to DS, are improved by dopaminergic therapy (Cools,
2006; Cools and D’Esposito, 2011; Cools et al., 2001, 2003; Frank, 2005; Frank et al., 2004; Hood
et al., 2007; Lewis et al., 2005; MacDonald and Monchi, 2011; MacDonald et al., 2011; Moustafa
et al., 2008a, 2008b; Shook et al., 2005; Slaboz et al., 2006; Tremblay et al., 2010). The detrimental
effects of dopaminergic therapy on cognition have been attributed to an overdose of dopamine in
regions of the brain (e.g., VS, orbitofrontal cortex (OFC), limbic regions, including hippocampus)
that receive dopamine from VTA (Cools, 2006; Cools and D’Esposito, 2011; MacDonald and
Monchi, 2011). Because the VTA is relatively spared in PD (Kish et al., 1988), regions supplied
by VTA have normal or near-normal levels of dopamine at baseline. Many researchers have
proposed that dopamine replacement therapy overdoses VTA-innervated brain regions, which
results in impaired function (Cools and D’Esposito, 2011; Cools et al., 2001, 2002, 2006; Dias et
al., 1996; Feigin et al., 2003; Ghilardi et al., 2007; Gotham et al., 1988; Graef et al., 2010; Seo et
al., 2010; Shohamy et al., 2006; Spaniol et al., 2009; Swainson et al., 2000; Tremblay et al., 2010).

Commonly, the effects of dopamine replacement therapy are tested using an exogenous dopamine
withdrawal procedure. Patients are instructed to abstain from taking dopamine precursors for a
minimum of 12 to a maximum of 18 hours, and dopamine agonists for a minimum of 16 to a
maximum of 20 hours before testing begins. This is referred to as the OFF state. Performance in
the OFF state is compared to performance in the ON state, which is characterized by testing
patients who are taking their regularly prescribed dopaminergic medications. Comparing
performance in ON and OFF states in a single patient allows within-subject differences to be
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examined. The effects of dopaminergic therapy performance are also understood by comparing
functions of PD patients to those of healthy controls. Although control participants are not
provided any dopamine replacement medications, they are also tested twice to understand how
potential practice, test-retest, and fatigue effects may contribute to performance.

1.4.2 Dopamine Overdose Hypothesis
A number of studies now confirm that at least some of the cognitive impairments that occur in PD
arise as a side effect of dopaminergic therapy. These results have been related to the dopamine
overdose hypothesis. Cognitive abilities mediated by relative dopamine-replete regions (i.e., VTAinnervated regions) are impaired by dopaminergic therapy, whereas abilities mediated by brain
regions that are dopamine-deplete at baseline (e.g., DS) are improved by dopaminergic therapy
(Figure 1.2).

The dopamine overdose hypothesis was first formulated by Gotham and colleagues (1988). They
tested PD patients both on and off medication in a series of tasks—with a one-week delay between
testing sessions. The ordering of on and off sessions was counterbalanced, and different versions
of each task was used in both sessions. PD patients in the OFF state made more errors in tasks that
probed decision-making and response selection processes compared to when they were tested in
the ON state. In contrast, PD patients in the ON state performed more poorly on tasks that involved
learning and working memory processes compared to when they were tested in the OFF state. As
such, Gotham and colleagues (1988) were the first to show these differential effects of
dopaminergic therapy in PD, and they explained their findings by the fact that learning and
working memory processes depend upon VTA-innervated brain regions which are dopamine
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replete in PD. As discussed below, subsequent studies have clearly demonstrated that decisionmaking and response selection implicates (Ali et al., 2010; Atallah et al., 2007; Daniel et al., 2010;
Grinband et al., 2006; Helie et al., 2010; Liu et al., 2010; Monchi et al., 2001; Rogers et al., 2000;
Seger et al., 2010; van Schouwenburg et al., 2010) or, in fact, depends (Benke et al., 2003; Cools
et al., 2006; Ell et al., 2006; Yehene et al., 2008; Rieger et al., 2003; Thoma et al., 2008; Vakil et
al., 2004) on DS, and that VTA-innervated regions, such as VS, limbic cortex (e.g., hippocampus),
and PFC are implicated in learning (Atallah et al., 2007; Feigin et al., 2003; Ghiladri et al., 2007;
Lisman and Grace, 2005; MacDonald et al., 2011; Reiss et al., 2005; Seo et al., 2010; Shohamy et
al., 2006; Tremblay et al., 2010) and working memory (Barbey et al., 2013; Lara and Wallace,
2015; Salazar et al., 2012; Wang et al., 2013), respectively.

Figure 1.2. Inverted-U function of dopamine levels and performance. The darker DS and VTA
symbols represent the effects of dopamine replacement therapy in PD. The lighter symbols
represent the effects of PD in the absence of dopamine replacement therapy. DS, dorsal striatum;
VS, ventral striatum; VTA, ventral tegmental area.
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1.5 Memory Impairments in PD
Early reports of explicit memory impairment in PD established these deficits as part of PD
progression itself, and not merely as a comorbidity of Alzheimer’s dementia (Helkala et al., 1988;
Sagar et al., 1988; Sahakian et al., 1988). Despite some contradictory findings (Taylor et al., 1990;
Weiermann et al., 2010), memory deficits are now a recognized symptom of PD (Aarsland et al.,
2009, 2011; Verbaan et al., 2007) and have been shown to worsen with disease progression
(Muslimovic et al., 2007).

1.6 Memory
Explicit memory refers to conscious, intentional remembering and can relate to general knowledge
or information about specific episodes, events, or personal experiences (Vandenbos, 2015).
Explicit memory can be further subdivided. Semantic memory refers to long-term memory for
factual information. Episodic memory refers to long-term memory for discrete events, with recall
of the time and place these memories were formed. Autobiographical memory refers to memories
from an individual’s life and is composed of both semantic and episodic memories. In contrast to
explicit memory, implicit memory refers to unconscious, unintentional remembering (Vandenbos,
2015). For example, implicit memory is invoked in the acquisition and later retrieval of procedural
skills—like those necessary to ride a bicycle. A skilled cyclist does not need to be able to verbally
describe how to ride a bike to be proficient; this skill is acquired in an unconscious manner over
repetitive attempts and can be accessed without conscious awareness. Implicit memory is also
implicated in repetition priming effects and learning and conditioning without awareness
(Schacter, 1987). For the purposes of the present study, we will be focusing specifically upon
explicit memory.
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1.6.1 Memory encoding
Successful remembering depends on effectively encoding and retrieving information. Memory
encoding is the process by which new information is transformed and stored in a long-term form.
This process occurs at synaptic and systems levels (Dudai, 2012).

At the synaptic level, it is theorized that encoding is initiated by a “teaching signal” that leads to
activation of intracellular signaling cascades resulting in posttranslational modifications,
modulation of gene expression, and protein synthesis that alter synaptic strength (Cohen and Frank,
2009; Dudai, 2012). These teaching signals have been identified as phasic responses in populations
of midbrain dopaminergic cells that burst-fire in response to positive feedback and have depressed
firing frequencies in response to negative feedback (Cohen and Frank, 2009; Schultz et al., 1997;
Frank, 2005; Frank and Fossella, 2011). These bursts and dips modify synaptic plasticity in
downstream brain regions (Wickens et al., 2003; Frank, 2005; Reynolds et al., 2001). Phasic
dopamine bursts result in long-term potentiation through D1 receptors of the direct pathway (Kerr
and Wickens, 2001; Kravitz et al., 2012; Reynolds et al., 2001; Shen et al., 2008). Long-term
potentiation is a process by which periods of synaptic activity produce long-term increases in
synaptic strength, facilitating future firing of these neurons (Baudry et al., 2015; Beaulieu and
Gainetdinov, 2011; Lisman et al., 2012; Malenka and Bear, 2004). Disinhibition of D2 receptors,
through the dissociation of dopamine from D2 receptors, as occurs during dopamine dips, increases
long-term potentiation in this cell population (Kravitz et al., 2012; Shen et al, 2008).
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The effects of dopamine on the direct and indirect pathways have been modelled by Cohen and
Frank (2009) in regards to Go (i.e., approach) and NoGo (i.e., avoidance) reinforcement learning.
Dopamine is viewed as playing a modulatory role in the basal ganglia. Agonism or facilitation of
D1 receptors is seen as enhancing the signal-to-noise ratio by relatively increasing the activity of
highly active cells that are responding in a pulsatile fashion and diminishing basal activity of cells
that are not. Agonism of D2 receptors, on the other hand, is always inhibitory. Bursts of dopamine,
as seen during the reception of positive feedback, facilitate Go activity through the direct pathway
and inhibits NoGo activity through the indirect pathway. On the other hand, dopamine dips, which
occur during the reception of negative feedback, decrease signal-to-noise in the direct pathway and
disinhibit cells in the indirect pathway, facilitating NoGo learning. Although Cohen and Frank
(2009) were discussing reinforcement learning specifically, the same actions of dopamine on direct
and indirect pathways are also exemplified motor control in PD. Because of decreased
dopaminergic tone, due to the loss of dopaminergic innervation from SN, PD patients experience
a biasing toward enhanced indirect pathway signaling, which leads to bradykinesia (Surmeier et
al., 2007). Given the above, the effects of dopamine on direct and indirect pathway signaling in
the basal ganglia may serve an explanatory role in the effects that medication and PD have on
memory encoding and retrieval.

At the systems level, there is abundant literature revealing that loss of integrity of the hippocampus
leads to dramatic failures in encoding new information explicitly. Early studies in patients with
medial temporal lobectomies revealed an inability to encode new explicit information—a
phenomenon known as anterograde amnesia (Milner, 1968, 1972; Scoville and Milner, 1957).
Using neuroimaging, explicit memory encoding has been shown to preferentially engage VTA-
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innervated medial temporal structures, such as the hippocampus (Schrager et al., 2008; Spaniol et
al., 2009). It has also been suggested that hippocampus and VTA form a functional loop that
regulates the encoding of information into long-term memory (Lisman and Grace, 2005). Lisman
and Grace (2005) propose that the hippocampus acts as a gate to this loop, such that if it detects
novel information, a signal is sent downstream, through the subiculum and VS, to the VTA, where
it contributes to the firing of dopaminergic cells in response to novelty. Subsequently, dopamine
is released to the hippocampus from the VTA and long-term potentiation is facilitated, leading to
encoding. Indeed, hippocampal activity has been detected during the presentation of novel stimuli
using single-unit recordings (Fyhn et al., 2002), positron emission tomography (PET; Tulving et
al., 1996), fMRI (Strange and Dolan, 2001; Yamaguchi et al., 2004) and c-Fos quantification
(Jenkins et al., 2004), which is a marker of cellular activity and gene transcription. Following the
proposed pathway from the hippocampus through the subiculum and VS to the VTA, it has been
found that VS cells fire in response to both subicular innervation (Wood and Rebec, 2004) and
novel stimuli (Ihalainen et al., 1999). Increased VS innervation then disinhibits the ventral
pallidum, which leads to increased firing of dopaminergic neurons in the VTA (Floresco et al.,
2003).

In addition to the novelty-dependent loop suggested by Lisman and Grace (2005), medial temporal
cortices have strong connections to the OFC and medial frontal areas (Petrides, 2007). These areas
both receive dopaminergic innervation from the VTA, and appear to be implicated in novelty
detection and processing, as well as in the valuation of stimuli and reward processing (Tzschentke
and Schmidt, 2000; Haber and Knutson, 2010). The OFC is connected bi-directionally via the
uncinated fasciculus to entorhinal and perirhinal cortices, as well as hippocampus and
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parahippocampus (Barbas, 1993; Barbas and Blatt, 1995; Catenoix et al., 2005; Cavada et al.,
2000). Monkeys with OFC lesions do not habituate to novel stimuli (Butter, 1964), and a
population of neurons in OFC (referred to as area 11) are selectively activated by novel, but not
familiar, stimuli in the absence of reward (Rolls et al., 2005). In humans, PET studies have
evidenced OFC activation when viewing novel faces, and this activity was positively correlated
with subsequent memory performance (Frey and Petrides, 2003). Interestingly, in another human
PET study, participants viewed two side-by-side abstract images. Some images had graffiti-like
designs superimposed on them. Participants were not required to make any decisions in regards to
these images; they simply pressed a button to proceed to the next set of images. Presentation of
images with graffiti-like designs activated OFC, indicating that viewing deviant visual stimuli
activated OFC (Petrides et al., 2002).

1.6.2 Memory Retrieval
Explicit memory retrieval refers to the act of accessing previously encoded information. This can
be accomplished by freely recalling information as when a participant is asked to first encode a
list of words or images and later generate the list of items without cues or prompts (i.e., free recall).
Serial recall is tested when a participant is asked to present the retrieved information in the order
in which it was encoded. Recall can also be cued (i.e., cued recall) when prompts or cues are
provided to help the participant retrieve the requested information. Finally, explicit memory
retrieval processes are also engaged when an individual is asked to recognize previously-presented
information from among newly-presented stimuli, as in a recognition memory test (Spaniol et al.,
2009).
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Synaptic and systems level accounts of memory retrieval are far less elaborated, and this area has
received much less research attention than memory encoding (Spaniol et al., 2009). In fact, at the
synaptic level, a consistent and sufficiently well-supported account for memory retrieval has not
yet been advanced. At the systems level, retrieval seems to implicate more distributed and varied
brain regions as detailed below.

A role for medial temporal structures has been demonstrated in free recall. For example, deficient
long-delay free recall has been found to correlate with smaller parahippocampal volume in PD
patients (Pirogovsky-Turk et al., 2015). Additionally, free recall performance has been shown to
correlate with integrity of the fornix, a white matter tract composed mostly of connections
associated with the hippocampal formation (Metzler-Baddeley et al., 2010, 2012). A posteromedial
network of brain regions, containing hippocampus, retrosplenial cortex and frontal regions, have
been shown to be engaged throughout free recall processes (Kragel and Polyn, 2013). Other brain
regions have also been consistently implicated in memory retrieval. Humans with dorsolateral PFC
(dlPFC) lesions evidenced recall deficits in a list learning paradigm of unrelated items with five
study-immediate recall phases (Gershberg and Shimamura, 1995). These patients had reduced
levels of self-initiated organization of list items and also reported less use of organizational
strategies. This finding is in line with other studies showing patients with frontal lobe lesions
evidence deficits in subjective organization in free recall paradigms (Eslinger and Grattan, 1994;
Stuss et al., 1994). Additionally, recent findings suggest that a dorsal frontoparietal network of
brain regions, including dlPFC, is transiently engaged early during free recall (Kragel and Polyn,
2013).
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Despite these findings in free recall reviewed above, most studies of memory retrieval have
focused on recognition memory (Spaniol et al., 2009), Spaniol and colleagues conducted a
quantitative meta-analysis of encoding and recognition memory related to neuroimaging.
retrieval—the latter measured during memory recognition tests. Further evidence for the role of
striatum, medial temporal cortices and frontal regions in memory encoding and retrieval are seen
in this meta-analysis (Spaniol et al., 2009). For the purposes of their encoding meta-analysis, they
included studies in which participants were imaged using fMRI while they were explicitly
encoding objects or words. To determine brain regions implicated in memory encoding, regional
brain activity was compared during encoding of subsequently-recognized items and encoding of
items that were later forgotten. Twenty-six studies were included in this part of the meta-analysis.
For the memory retrieval analysis, they included studies in which participants were imaged while
they were performing a recognition memory test. In a recognition memory test, participants are
asked to indicate whether they believe a displayed item is “old” and was previously presented to
them during the encoding or study period or whether they believe the displayed item is “new” and
did not appear at study. The contrast of interest in the retrieval portion of their meta-analysis was
regional brain activity correlating with correct “old” item presentations, referred to as “hits”,
compared to activity during correct “new” item presentations, referred to as “correct rejections”.
Thirty studies were included in this part of the meta-analysis.

For encoding, not surprisingly, they found preferential activation in many VTA-innervated
regions, including medial temporal structures such as the hippocampus, parahippocampal gyrus,
and amygdala, as well as VTA-innervated frontal regions. For the retrieval meta-analysis, many
VTA-innervated regions were also activated during recognition memory testing, including
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parahippocampal gyrus, VS, and frontal regions. In addition, however, there were large clusters of
activation found in DS and several in dlPFC, a primary cortical partner of DS (Alexander et al.,
1986; Postuma and Dagher, 2006). Further, the encoding and retrieval contrasts were then
contrasted with one another to determine which brain regions were preferentially engaged during
encoding and retrieval. Many medial temporal and frontal structures were engaged for both
encoding and retrieval. Hippocampus and amygdala were found to be preferentially engaged
during encoding, whereas DS and frontal regions, which are reciprocally connected to DS, such as
dlPFC, frontal eye fields, and motor cortices were preferentially engaged during retrieval. In sum,
this meta-analysis provided evidence for VTA-innervated regions playing a role in memory
encoding and DS, and dorsal frontal regions functionally connected to DS, are engaged during
retrieval processes.

1.7 Memory Encoding and Retrieval in PD
Successful memory depends upon both an encoding phase, where new information is transferred
from working memory to long-term memory, as well as a retrieval phase, during which long-term
memory is successfully retrieved from long-term memory stores. Impaired remembering can arise
due to impairments in either encoding or retrieval. In PD, few studies have investigated memory
encoding and retrieval separately. In those that did, most investigated memory impairment in PD
patients who were on their usual dopaminergic medication only. As we have detailed above,
dopaminergic therapy can have complex effects on cognition. Without an off medication
comparison, it cannot be known whether deficits owe to PD pathophysiology or medication
overdose effects. Further, normal performance in PD patients tested only in the ON state could
reflect either intact encoding and retrieval, or baseline memory impairment that is improved by
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medication. In this way, interpretation of these results is mired. Reviewing these memory studies
in PD patients in the ON state only has further revealed highly inconsistent findings. Some studies
found deficits only in encoding (Chiaravalloti et al., 2014; Ellfolk et al., 2013; Knoke et al., 1998;
Pirogovsky-Turk et al., 2015), others only in retrieval (Ellfolk et al., 2012; Higginson et al., 2005),
whereas some found impairments in both domains (Ibarretxe-Bilbai et al., 2011; Vingerhoets et
al., 2005).

Few studies have been conducted in PD patients off dopaminergic medication. In a study of verbal
list learning, drug-naïve PD patients evidenced both encoding and retrieval deficits (Bronnick et
al., 2011). Encoding deficits were found in the PD patient group. These deficits were not predicted,
given our review of the literature clearly implicating VTA-innervated structures in encoding and
the fact that VTA-innervated brain regions are relatively dopamine replete, especially at early
stages of disease. As such, these encoding deficits may be resultant from the chosen methodology.
This study used a verbal list learning paradigm, with list items belonging to one of four semantic
categories. On closer evaluation, a regression analysis showed that the encoding deficit in these
drug-naïve patients was attributable to an inability to use semantic clustering as a learning strategy.
As such, this deficit might not have reflected deficient memory encoding per se, but may have
been related to impaired semantic organizational processes. These processes have been shown to
implicate DS and dorsal frontal networks (Seger et al., 2010; Helie et al., 2010), especially in
ambiguous contexts (Daniel et al., 2010). Frontal lesion patients have previously been shown to
evidence deficits in self-directed organization of list items during recall (Eslinger and Grattan,
1994; Gershberg and Shimamura, 1995; Stuss et al., 1994). DS is significantly dopamine depleted,
even early in PD, and functions supported by this structure and its cortical partners are expected
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and consistently observed. As predicted, PD patients also evidenced deficient free recall, both after
short and long delays, compared to controls (Bronnick et al., 2011). This is consistent with brain
regions that have preferentially been implicated in explicit retrieval processes (Spaniol et al.,
2009).

Few studies to date have examined memory deficits in PD using an ON-OFF paradigm. Review
of the literature revealed four previous ON-OFF PD studies of memory. However, two of these
studies did not separate memory performance into encoding and retrieval processes (Drag et al.,
2009; Edelstyn et al., 2010). Failure to separately assess encoding and retrieval processes as well
as to evaluate the distinct effects of PD and dopaminergic therapy in ON-OFF designs have yielded
significant inconsistencies in the PD memory literature. Encoding and retrieval depend on different
brain regions—as detailed above—and, given our current understanding of the pathophysiology
of cognitive dysfunction in PD, these operations are expected to be dissimilarly affected by
dopamine replacement. The degree to which a particular memory evaluation stresses encoding
relative to retrieval is expected to determine how PD patients perform in the OFF and ON states.

Only two studies have investigated encoding and retrieval separately in PD using an ON-OFF
design. Grogan and colleagues (2015) tested memory encoding and retrieval using the Hopkins
Verbal Learning Task-Revisited in PDs and healthy controls. This is an episodic memory test that
assesses encoding and delayed recall. On Day 1, 12 words from three semantic categories were
read aloud to participants, who were instructed to recall as many words as they could after each
verbal presentation. There were three study-immediate recall phases. The total number of items
recalled during these three immediate recall phases was considered as a measure of encoding. After
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a 30-minute delay, participants recalled as many items as they could. On Day 2, participants were
asked to recall these items once again without being provided any additional study sessions. PD
patients completed these two days of testing in either OFF-OFF, OFF-ON, ON-ON, or ON-OFF
medication orders. Overall, controls outperformed PDs on measures of encoding and delayed
recall, independent of medication status. On Day 2, PD patients revealed superior delayed recall
in the ON relative to the OFF state. Further, the OFF-ON PD group, in particular, clearly
outperformed all other medication groups on Day 2. This pattern is entirely predictable based on
brain regions suggested to mediate encoding and retrieval processes respectively—as reviewed
above (e.g., Spaniol et al., 2009)—combined with the differential effects of dopamine replacement
medication on VTA-innervated brain regions and those areas receiving dopamine from SN,
particularly DS (Cools et al., 2006; MacDonald & Monchi, 2011). Encoding has been shown to
depend on and implicate VTA-innervated brain regions, particularly hippocampus, OFC, and VS
(Frey and Petrides, 2003; Lisman and Grace, 2005; MacDonald et al., 2013; Milner, 1968, 1972;
Scoville and Milner, 1957; Spaniol et al., 2009). In contrast, retrieval preferentially implicates DS
and frontostriatal loops containing DS (Eslinger and Grattan, 1994; Gershberg and Shimamura,
1995; Kragel and Polyn, 2013; MacDonald et al., 2013; Spaniol et al., 2009; Stuss et al., 1994).
VTA-innervated brain regions are dopamine replete and function normally in the OFF state for PD
patients, particularly early in disease (Kish et al., 1988). Performance actually worsens due to
dopamine overdose in the ON state for functions mediated by VTA-innervated brain regions. In
contrast, DS is significantly dopamine depleted, with clear impairment in the OFF state for
functions mediated by DS or cortical networks implicating DS. These deficits are improved by
treatment in the ON state. In this way, the observed results are easily interpreted as owing to more
successful encoding for PD patients in the OFF state on Day 1 and better retrieval for PD patients
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in the ON state on Day 2. Consistent with this interpretation, on Day 1, absolute recall after a 30min delay was performed better in the OFF than ON state, the reverse of the pattern on Day 2.
These results are presented in Figure 1.3.

Figure 1.3. Percentage of verbally-presented items successfully recalled after 30-minute and
24-hour delays. PD patients completed these two recall session in either ON-ON, OFF-ON, ONOFF, or OFF-OFF medication orders. Healthy control data is shown in black. PD patients who
were tested in the OFF-ON order outperformed all other PD groups on 24-hour delayed free recall.
Reproduced from Grogan and colleagues (2015).

The results of Grogan and colleagues (2015) essentially replicated those of MacDonald and
colleagues (2013), who conducted a similar study that isolated encoding and retrieval processes in
PD patients. Patients were tested both on and off medication on two consecutive days, using
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different stimulus sets on each day, alongside healthy, age- and education-matched controls, with
ON-OFF order counterbalanced across participants. Controls were not given any dopamine
replacement medication, but were tested on both days with their session yoked to their agematched control and analyzed in this way. This was to account for potential fatigue, order, or
practice effects that owed to performing memory tests on two consecutive days. Two memory
tasks were used. The first was the Rey Auditory Verbal Learning Test (RAVLT). This is a test of
verbal explicit memory. In each testing session, a list of 15 words, List A, was presented one-ata-time on a computer screen. Participants were instructed to remember as many of these words as
possible. After all 15 words have been displayed, participants are given one minute to write down
as many words as they can remember. This study-immediate recall procedure was repeated three
times. After the last presentation of List A, a second list of 15 different words, List B, was
presented, but only for a single iteration of the study-immediate recall procedure. After this
interference list and again after a 30-minute delay, participants were asked to recall as many items
as they could from List A without further any intervening study experiences. During the recall test
after a 30-minute delay, participants were also asked to provide as many words as they could
remember from interference List B. The second memory test was the Aggie Figures Learning Task
(AFLT). This task is a non-verbal analogue of the RAVLT. In this task, the same procedures were
followed, except that 15 abstract symbols were presented instead of 15 words and there were five
study-immediate recall phases rather than three in the RAVLT. All other aspects of the AFLT and
the RAVLT were the same. The measure for encoding in this study was the difference in the
number of items recalled during the final study-immediate recall phase and the first studyimmediate recall phase in both the RAVLT and AFLT. The items successfully recalled in the first
study-immediate recall phase were subtracted to control for the effects of working memory and
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immediate recall abilities. This subtraction serves to better isolate the memory encoding process
(i.e., the extent to which items are transferred from working memory into long-term memory)
throughout these study-immediate recall phases. Further, this strategy aims to eliminate effects
related to retrieval ability on performance, as retrieval ability is expected to contribute to
performance equally for the first and the last study-immediate recall phases. In contrast, memory
retrieval was measured by combining the number of items successfully recalled from Lists A and
B in the RAVLT and AFLT after the 30-minute delay. Retrieval scores were normalized to the
number of items encoded on the final study-immediate recall phase, to account for effects that
were related to superior encoding.

When analyzing the memory encoding measure, MacDonald and colleagues found that PD patients
performed equivalently to controls while off medication, but encoded more poorly than controls
when on medication. Further, PD patients in the OFF state encoded significantly more items than
PD patients in the ON state from first to final study-immediate recall phases. This compromised
memory encoding (i.e., lower learning rates resultant from not properly encoding symbols into
long-term memory) in PD patients while on medication was attributed to a possible overdose of
DA in VTA-innervated regions which have been shown extensively to underlie memory encoding
(Atallah et al., 2007; Grogan et al., 2015; Hiebert et al., 2014; Lisman and Grace, 2005;
MacDonald et al., 2013; Spaniol et al., 2009). In early PD, the VTA is relatively spared (Kish et
al., 1988). As such, the administration of exogenous dopamine can lead to overdose of VTAinnervated regions (see Cools et al., 2006; MacDonald and Monchi, 2011 for reviews).
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In the recall task, they found that PD patients performed worse than controls while off medication
and equivalent to controls when on medication. The within-subject contrast also revealed that PD
patients recalled significantly more items when they were tested on relative to off medication. The
improved performance of PD patients on medication was attributed to evidence that DS and its
cortical partners mediate retrieval and to the fact that DS is significantly dopamine depleted even
in early PD. Indeed, dopamine replacement therapy has been shown to reliably improve motor and
cognitive performance that relies on DS throughout the disease course (Cools, 2006; MacDonald
and Monchi, 2011). As previously detailed, DS and regions reciprocally connected to DS have
been implicated in retrieval processes (Gershberg & Shimamura, 1995; Eslinger & Grattan 1994;
Spaniol et al., 2009). DS is preferentially activated when recognizing remembered items in an
episodic recognition test (Kim, 2010), as well as during explicit remembering of category
membership (Seger et al., 2010; Helie et al., 2010; Hiebert et al., 2014).

In summary, the only studies that have looked at encoding and retrieval in PD, accounting for
differential effects of dopaminergic therapy on these separate processes, are consistent. Both
suggest that encoding is intact in PD at baseline and is worsened by dopaminergic medication,
whereas retrieval is impaired in the OFF state and is improved by dopamine supplementation. This
is in line with the memory literature that consistently shows that memory encoding is mediated by
VTA-innervated brain regions (Atallah et al., 2007; Grogan et al., 2015; Hiebert et al., 2014;
Lisman and Grace, 2005; MacDonald et al., 2013; Spaniol et al., 2009). VTA-innervated brain
regions are relatively dopamine replete at baseline in PD but are overdosed by dopamine therapy
in levels titrated to DS dopamine depletion. In contrast, retrieval (e.g., recall and recognition
memory processes) implicate more distributed brain regions, including DS and cortical regions to
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which it is reciprocally connected (Gershberg & Shimamura, 1995; Eslinger & Grattan 1994; Kim,
2010; Spaniol et al., 2009). DS is seriously dopamine depleted in PD in the OFF state and this is
improved with dopaminergic supplementation. In this way, these results are easily understood in
light of the pathophysiology of PD

1.8 Influence of Genotype on Encoding and Retrieval
A number of genes influence baseline DA levels as well as responsivity to DA receptor stimulation.
These are presumed to affect cognitive processes as well as to interact with PD pathophysiology.
Further, it is expected that these genes interact with exogenous dopamine. Polymorphisms in the
gene coding for dopamine transporter (DAT1) are of particular interest in PD.

1.8.1 DAT1
DAT1 is a Na+/Cl—dependent plasma membrane transporter protein that reabsorbs synaptic
dopamine into presynaptic terminals (Jaber et al., 1997). DAT1 is abundant in the striatum,
midbrain, and hippocampus, but scarce and located at a distance from synaptic sites in PFC (Lewis
et al., 2001; Sesack et al., 1998; Schott et al., 2006). SLC6A3, the gene coding for DAT1, is located
on chromosome 5p15.3 (Kawarai et al., 1997). A 40-base pair variable nucleotide tandem repeat
(VNTR) element is located in the 3’ untranslated region and is repeated 3-13 times, with 9- and
10-repeat forms being most prevalent, with ~29% and ~69% prevalence in Caucasian populations,
respectively (Kang et al., 1999; Sano et al., 1993). Because this VNTR is located in an untranslated
region of the SLC6A3 gene, it does not alter protein structure, but may influence DAT1 expression
through other mechanisms (Faraone et al., 2014). Recent meta-analyses have concluded that
expression of DAT1 9-repeat allele (9R) is ostensibly higher than the 10-repeat allele (10R; Costa
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et al., 2011; Faraone et al., 2014) though several earlier studies had concluded the opposite
(Jacobsen et al., 2000; van de Giessen et al., 2009; van Dyck et al., 2005). Therefore, in line with
recent meta-analyses, 9R homozygotes are expected to have lower concentrations of synaptic and
extra-synaptic dopamine compared to 10R carriers at baseline. This is explained by the fact that
increased DAT1 expression leads to greater dopamine reuptake.

1.8.2 DAT1 Genotype and Cognition
In 9R carriers, increased expression of DAT1, and consequently lower concentrations of synaptic
and extra-synaptic dopamine at baseline, are expected to enhance the ratio between phasic,
pulsatile, dopamine bursts related to events such as reward, positive feedback, or behavior, and
tonic, basal dopamine release that occurs at rest. This enhanced signal-to-noise ratio is expected
to result in more efficient signaling and potentially improved performance; however, given that
this superior performance is expected on the basis of lower tonic, basal dopamine, 9R carriers are
predicted to be more susceptible to overdose effects of exogenous dopamine.

In line with the hypothesis that 9R carriers have more efficient dopamine signaling and potentially
improved performance, 9R carriers have been shown to have enhanced bilateral activity in striatum
upon the reception of positive feedback (Forbes et al., 2009; Hariri et al., 2006). Dreher and
colleagues (2009) also found that 9R carriers had greater reactivity in the midbrain and lateral PFC
upon the reception of reward and, further, showed enhanced reactivity in DS and VS during reward
anticipation. Two studies of reward-related activity in VS did not find effects of DAT1 until they
accounted for additional dopaminergic polymorphisms (Nikolova et al., 2011; Yacubian et al.,
2007). Nikolova and colleagues (2011) created a cumulative dopamine score for participants using
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polymorphisms in DAT1, the D2 receptor, catechol-O-methyltransferase (COMT), and D4
receptor genes. When accounting for all these genotypes simultaneously, they found that dopamine
scores accounted for 11% of the variability in VS reactivity in response to the reception of positive
feedback, though they included the 10R allele in the high-dopamine set of polymorphisms.
Yacubian and colleagues (2007) found increased VS reactivity in response to reward anticipation
only when 9R carriers were also carriers of a COMT allele that leads to increased dopaminergic
concentrations in PFC. Interestingly, 10R/10R homozygotes who carried all wild-type COMT
alleles evidenced increased VS reactivity, similar to 9R carriers with increased PFC dopamine
concentrations. These results indicated that only a high dopamine-low dopamine pairing of DAT1
and COMT alleles led to increased VS reactivity due to reward anticipation. Further, in a PET
study of habitual smokers, increased smoking-related VS reactivity—hypothesized to be due to
larger phasic dopamine bursts in 9R carriers, who have lower tonic synaptic dopamine
concentrations—was seen in 9R carriers relative to 10R/10R homozygotes (Brody et al., 2006).
9R carriers, as compared to 10R/10R homozygotes, have also been shown to evidence a larger
frontoparietal, novelty-dependent electroencephalographic response during the presentation of
auditory cues signaling a task switch during a test of cognitive flexibility (Garcia-Garcia et al.,
2010). These results suggest that 9R carriers are more sensitive to phasic increases in dopamine in
the striatum.

This sensitivity in 9R carriers was also observed in a study of the effects of DAT1 genotype on
memory encoding and retrieval. Schott and colleagues (2006) examined the effects of DAT1
genotype on memory encoding and retrieval in healthy participants in a study-recall task.
Participants studied a list of 20 words in an MRI scanner, one-at-a-time until all words had been
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presented. After a 90-second distractor task, they were asked to recall as many of the words as they
could. This study-recall procedure repeated three times. Although DAT1 genotype did not affect
subsequent remembering of list words, interesting differences in brain activations were seen.
During successful encoding, determined by subsequent performance in the recall phase, expected
midbrain, fronto-parietal-occipital, and limbic activations were observed. Interestingly, 9R carriers
showed stronger activations in VS, inferior PFC, and anterior cingulate at the time of encoding for
successfully remembered items. Further, during subsequent recall, 9R carriers showed stronger
activation of midbrain/SN. DAT1 genotype was also shown to affect the functional coupling
between hippocampus and PFC during successful encoding. Collapsing across genotype, they
found the expected increase in functional connection between hippocampus and dorsal PFC and
OFC. 9R carriers showed increased functional coupling between the hippocampus and both the
OFC and VS, however. Taken together, although no differences were seen at the behavioural level
between DAT1 genotypic groups, 9R carriers were more sensitive to activity-induced
dopaminergic modulation both within the striatum and in regions to which it is anatomically and
functionally connected.

The sensitivity of 9R carriers to exogenous dopamine was examined in a study probing the
interactive effects of dopaminergic medication and DAT1 genotype on learning about others’
prosociality. Eisenegger and colleagues (2013) tested healthy controls on either 300 mg of L-dopa
or a placebo while participating in a task that required them to learn about the behavior of an
automated second player in a monetary exchange task. The participants started out with 10
arbitrary units of money. On each trial they were instructed to transfer any amount of their money
to a second player. Transfers had an 80% probability of reaching the second player. Transfers that
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successfully arrived to the second player were tripled in value. If the transfer did reach the second
player, they could choose to either make a repayment to the first player that equalized the payout,
or they could choose to keep the entire amount. For the 20% of transfers that did not make it to the
second player, the second player received nothing and could not make a repayment. This stochastic
delivery of transfers ensured that participants could not determine with certainty the trials on which
the second player opted not to repay versus trials on which the transfer did not occur and repayment
was precluded. In the experiment, there were two types of second players: a prosocial player, who
made repayments the majority of the time, and an antisocial player, who made infrequent
repayments. There were no medication or genotypic effects when participants were paired with an
antisocial player. In regards to prosocial second players, however, 9R carrier participants on Ldopa, compared to on placebo, secured less earnings, while 10R/10R participants on L-dopa
secured more earnings than when they were on placebo.

Given the complexity of this task, maximizing earnings likely reflects both learning about the
behavior of the second player and using this information for strategic decision-making. Given the
design of this study, these processes could not be disentangled. Nonetheless, in line with
predictions, 9R carriers evidenced dopamine overdose effects that produced either impaired
learning about behavior or deficient decision making. In contrast, 10R/10R participants benefitted
from exogenous dopamine producing either improved learning or superior decision making.

Taken together, these studies suggest that 9R carriers are more sensitive to elicited pulsatile or
phasic dopamine, particularly in the striatum, as well as in functional cortical partners. These
effects have been noted during successful encoding and retrieval, as seen through enhanced
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regional brain activity and functional connectivity. 9R carriers were also shown to be more
sensitive to dopamine overdose.

1.9 Aims of the Present Study
The aim of the current study was to investigate how differences in DAT1 affect baseline memory
encoding and retrieval performance in healthy elderly controls. Foremost, we planned to
investigate how polymorphisms in this gene interact with PD pathophysiology and dopaminergic
therapy to affect memory encoding and retrieval performance. We intended to implement a study
similar to MacDonald and colleagues (2013) with separate encoding and recall measures,
investigating these effects in both the ON and OFF states in PD.

This study was designed to investigate the role of a dopaminergic polymorphism (DAT1 40-basepair VNTR) on memory encoding and retrieval in PD patients on and off medication as well as in
healthy controls. Identifying gene-medication interactions for cognitive symptoms in PD patients
would be important from both a clinical and basic science standpoint. Clinically, identifying genes
that interact with medication in certain cognitive domains could lead to treatment paradigms that
account for a wider spectrum of potential complications and side effects. Additionally, this study
could yield valuable insights on the mechanisms of memory encoding and retrieval by taking into
account variation in endogenous dopamine signaling and their potential interactions in the
presence of exogenous dopamine.

1.10 Hypotheses/Predictions
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In healthy controls, we predicted superior encoding scores in DAT1 9R carriers, but did not expect
genotype to affect recall scores.

Overall, for PD patients off medication, we expect to see a similar pattern of effects as in the
control group for encoding, with 9R participants outperforming 10R/10R participants. In addition,
based on previous research (MacDonald et al., 2013; Grogan et al., 2015), we expect PD patients
off medication to perform equivalently to controls in the encoding task. On medication, we further
predict that 9R PD patients will be more sensitive to overdose from exogenous dopamine and,
hence, will have greatest impairment in performance relative to off performance. For recall, we
expected PD patients to perform more poorly than controls regardless of genotype, and further that
all PD patients would recall more items in the on than off dopamine state.

2.0 Methods
2.1 Participants
Forty-five patients with PD participated in the study. Patients were diagnosed by a licensed
neurologist and met the core assessment criteria for diagnosis of idiopathic PD for surgical
interventional therapy and the UK Brain Bank criteria for PD. All patients who participated in this
study were referred directly from licensed neurologists. Patients who were recruited were asked to
bring a control participant (e.g., spouse, relative, friend) with them if possible who was of a similar
age and had completed a similar number of years of education. Controls were also recruited from
a pre-existing database if particular patients could not bring a control participant with them. Fortytwo healthy control participants were tested as well. Patients and controls were excluded if they
were previously diagnosed with dementia or mild cognitive impairment, if they reported loss of a
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previous level of function related to cognitive problems, or if they scored less than 22/30 on the
Montreal Cognitive Assessment (MOCA). Further, participants were excluded if they were
abusing alcohol, prescription or street drugs, or taking medications such as donepezil, galantamine,
rivastigmine, memantine, or methylphenidate. Participants were also excluded if they were
depressed or anxious enough to require treatment from a psychiatrist or if they had any
neurological illnesses. This study was approved by the ethics review board of both the Sudbury
Regional Hospital (Sudbury, Ontario, Canada), and the University of Western Ontario (London,
Ontario, Canada). All participants provided informed consent prior to testing according to the
Declaration of Helsinki (1991).

Presence of disease as well as severity were assessed for all patients both on and off dopaminergic
medication using the motor subscale of the Unified Parkinson’s Disease Rating Scale (UPDRS)
by a licensed movement disorders neurologist. All controls were screened for signs of PD and a
score was assigned to them on the UPDRS. None were judged to have PD. All patients and no
controls were treated with dopamine replacement medications such as L-dopa and/or dopamine
agonists. Eighteen Patients were taking dopamine agonist medication. Table 2.1 presents mean
group demographic information, screening affective and cognitive measures, and daily dose of
DA-replacement medications in L-dopa equivalents. Calculation of daily L-dopa equivalent dose
for each patient was based on theoretical equivalence to L-dopa (Evans et al., 2004) as follows: Ldopa dose + L-dopa dose x 1/3 if on entacapone + bromocriptine (mg) x 10 + cabergoline or
pramipexole (mg) x 67 + ropinirole (mg) x 20 + pergolide (mg) x 100 + apomorphine (mg) x 8.
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Two participants from each group were excluded because of an inability to properly determine
their genotypes for the DAT1 gene. As such, 43 PD patients and 40 controls were included in our
subsequent analyses.

Table 2.1: Demographic and screening data for PD patients and controls separated by
genotype
PD
Control
10R/10R
9R
10R/10R
9R
n
29
14
26
14
Age
68.03 (1.40)
69.14 (1.80)
64.42 (1.13)
67.54 (2.02)
Education
15.17 (0.51)
14.35 (0.86)
14.50 (0.48)
13.46 (0.66)
Years Disease
6.83 (1.31)
6.27 (1.30)
LED (mg)
683.60 (63.69)
687.63 (86.87)
DA (n)
13
5
BDI-II (ON)
8.07 (1.16)
10.43 (1.34)
3.31 (0.72)
3.07 (1.22)
BDI-II (OFF)
8.44 (1.05)
10.93 (1.51)
3.81 (0.88)
4.21 (1.39)
BAI (ON)
8.59 (1.27)
12.00 (2.63)
3.19 (0.72)
3.43 (1.09)
BAI (OFF)
9.90 (1.52)
11.50 (1.92)
2.69 (0.67)
2.71 (0.70)
SAS (ON)
11.93 (1.01)
12.50 (1.42)
9.62 (0.82)
9.86 (1.32)
SAS (OFF)
11.41 (1.15)
11.50 (1.32)
9.69 (0.94)
9.21 (1.48)
ANART IQ
122.45 (1.53)
123.917 (2.40)
123.27 (1.51)
123.11 (2.00)
F-Words
13.45 (0.77)
16.62 (1.83)
14.35 (0.84)
14.93 (1.01)
A-Words
10.07 (0.81)
13.46 (1.66)
12.04 (0.81)
13.00 (1.37)
S-Words
13.41 (0.90)
17.92 (1.99)
15.15 (0.82)
15.07 (1.43)
Animals
19.03 (1.12)
19.69 (1.74)
20.64 (1.21)
21.00 (1.01)
MOCA
25.79 (0.43)
26.86 (0.61)
27.62 (0.52)
27.07 (0.62)
All values reported are group means (SEM). Education refers to the number of years spent in the
education system. Controls were not given dopaminergic medication, but their data are presented
to correspond to the ON-OFF order of the PD patient to whom they were matched. Elaboration of
measures used in table follow below.
Education = years of education; Years Disease = years since diagnosis of PD; LED = daily LDOPA equivalent dose in mg; DA = number of PD patients who were taking dopamine agonist
drugs; BDI-II = Beck Depression Inventory II score; BAI = Beck Anxiety Inventory score; SAS
= Starkstein Apathy Scale scores; ANART IQ = National Adult Reading Test (Nelson and
Willison, 1991) IQ estimation (tested in the ON session only); F-, A-, or S-Words = number of
words beginning with the letter F, A, or S, respectively, generated in 60 s (tested in the ON session
only); MOCA = total score on the Montreal Cognitive Assessment.
When examining the effect of DAT1 genotype on our demographic and screening measures within
the PD patient and control groups, we found no significant differences in any measure in either
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group (Table 2.1). We also noted a significant difference in both age (t = -2.01, p = 0.05) and
MOCA scores (t = 2.72, p < 0.01) between our 10R/10R PD patients and 10R/10R controls. No
statistically significant differences were seen between 9R carrier PD patients and controls. When
collapsing across genotype, PD patients had higher scores than controls on the Beck Depression
Inventory-II and Beck Anxiety Inventory during both the on and off medication sessions and on
the Starkstein Apathy Scale during the on medication session. This is a common finding (Aarsland
et al., 2011; Broen et al., 2016; den Brok et al., 2015). Despite these higher scores, no PD patients
(or controls) were moderately or severely depressed or anxious. We used an a priori cutoff of 28
(i.e., moderate depression) for the BDI-II and BAI for exclusion, but no participants approached
this cutoff for either inventory. Finally, PD patients had statistically significantly lower MOCA
scores than heathy controls, though means for both groups were within normal limits.

2.2 Genotyping Procedure and Results
Saliva samples were collected from participants using Oragene 2 mL DNA collection kits (DNA
Genotek, Ottawa, Ontario, Canada). A 40-base-pair VNTR located in the 30 -untranslated region
of the DAT1 cDNA was amplified using polymerase chain reaction from genomic DNA using 5
U of Taq DNA polymerase. An initial denaturation was completed for 3 min at 95.1 C. Afterward,
35 cycles of denaturing at 93.1 C for 45 s, annealing at 67.5 C for 45 s, and extension at 72.1 C
for 45 s were performed, all in the presence of primers 50-TGT GGT GTA GGG AAC GGC CTG
AG-30 and 50-CTT CCT GGA GGT CAC GGC TCA AGG-30. A final extension was then
completed at 72.1 C for 3 min. polymerase chain reaction amplification was carried out in a final
volume of 25 mL consisting of 80 ng of genomic DNA, 250 mM of each deoxyribonucleotide, 10
pmol of sense and antisense primers, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, and 1.5 mM MgCl2.
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66.7% of participants were homozygous for the 10R allele and 33.3% of participants were carriers
of a single 9R allele and a 10R allele. No participants were homozygous for the 9R allele. The
DAT1 gene was shown to be in Hardy-Weinberg equilibrium (2 test, p = 0.067). DAT1 genotypic
frequency was similar for control (10R/10R: 65%, 9R: 35%) and PD patient (10R/10R: 68.2%,
9R: 31.8%) groups.

2.3 Design and Procedure
Participants performed two versions of the AFLT on two consecutive days. PD Patients completed
the AFLT once while on their dopamine-replacement therapy and once while off dopaminereplacement therapy. We counterbalanced the ON-OFF order such that half the participants first
completed the task while ON and the other half first completed the task while OFF. PD patients
took their medication as per their neurologist’s instruction in ON sessions. Patients were instructed
to abstain from taking L-dopa for a minimum of 12 to a maximum of 18 hours, and dopamine
agonists for a minimum of 16 to a maximum of 20 hours before testing began in the OFF state.
Control participants were also tested on two days, although control participants were not given any
dopamine-replacement medication. By testing control participants on two consecutive days, and
analyzing their data to correspond to the PD patient to whom they were matched, we controlled
for any potential order, fatigue, or practice effects related to repeatedly performing different
versions of our memory measures.

In each session, a set of 15 abstract symbols, List A, was presented to participants. These symbols
were presented one at a time for 1000 ms in the centre of a computer monitor. Participants were
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instructed to try to remember as many of these symbols as possible. After the entire list had been
presented, the participant was given 60 s to draw all the symbols they could remember onto a piece
of paper. This study-immediate recall procedure for List A was repeated five times in each version
of the AFLT task.

A second set of 15 abstract symbols, List B, was then presented using parameters identical to those
above, but List B was only presented a single time. Participants were then given 60 s to draw all
the symbols they could remember after the presentation List B. Next, participants were asked to
draw all the symbols that they could recall from List A again.

After a 30-minute period of delay, during which participants performed distractor tasks (a number
comparison task not reported here), participants were asked to draw all the symbols that they could
freely recall from Lists A and B.

Appendices 5.1-5.4 present Versions 1 and 2 of Lists A and B. Versions 1 of all lists was used on
Day 1 and Versions 2 of all lists were used on Day 2, regardless of ON or OFF medication status.
In this way, an equal number of PD patients performed Versions 1 and 2 lists in the ON and OFF
states.

2.4 Data Analysis
The AFLT was scored by two researchers who were blinded to the identity of the participant (ie.,
PD or Control) and session (i.e., ON or OFF state). A single point was awarded for each recalled
item that could be unambiguously identified. Therefore, items were classified as correct if they
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had minor distortions in their shape or orientation. Any discrepancies in scoring between the two
scorers were addressed such that an agreement was reached concerning scoring of these items.

The difference in the number of correctly recalled items from the first and final study-immediate
recall phases was used as our metric of memory encoding (Vakil et al., 1998, 2010; Mitrushina, et
al., 2005; Vakil & Blachstein, 1993; Woodard et al, 1999; Crawford et al., 1989). That is, the
number of items successfully recalled in the first study-immediate recall phase was subtracted
from the number of items successfully recalled in the final study-immediate recall phase. This was
to control for the effects of working memory and immediate recall abilities. This subtraction serves
to better isolate the memory encoding performance. This strategy aims to eliminate effects related
to retrieval ability on performance, as retrieval ability is expected to contribute to performance
equally for the first and the last study-immediate recall phases, with differences across phases
owing more to a participants’ encoding (Vakil et al., 1998, 2010; Mitrushina, et al., 2005; Vakil &
Blachstein, 1993; Woodard et al, 1999; Crawford et al., 1989).

We used the total number of items recalled from List A after the 30-minute delay divided by the
total score achieved in the final study-immediate recall phase as our measure of memory recall.
Unlike study-immediate recall phases, recall after delay is believed to preferentially index retrieval
processes (Wixted and Ebbesen, 1991). Further, by correcting for the number of items recalled on
the final study-immediate recall phase, retrieval can be assessed in a less biased manner,
controlling for differences between individuals in encoding ability.
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Encoding scores and weighted recall scores were used as dependent measures in two separate
2x2x2 mixed-design analyses of variance (ANOVA) with Group (PD vs. Control) and Genotype
(DAT1 10R/10R vs. 9R carriers) as between-subject factors, and Session (ON vs. OFF) as the
within-subject variable. Where warranted by significant interaction results, we followed up with
subsequent 2x2 mixed ANOVAs with Group (PD vs. Control) or Genotype (DAT1 10R/10R vs.
9R carriers) as the between-subject factors and Session (ON vs. OFF) as the within-subject
variable. If justified by the analyses described above, we investigated further in one-way ANOVAs
with Session (ON vs. OFF) as the within-subject factor to explore the simple effects of Session
within Group and/or Genotype.

3.0 Results
3.1 Encoding Phase
We examined encoding scores in the AFLT in a 2x2x2 mixed ANOVA with group (PD vs.
Control) and DAT1 genotype (DAT1 10R/10R vs. 9R carriers) as between-subject factors, and
Session (ON vs. OFF) as the within-subject variable (Table 3.1; Figure 3.1). We found a
marginally significant main effect of Group with lower encoding scores for PD compared to
Controls [F (1, 79) = 3.327, MSE = 8.137, p = 0.072]. Session x Group [F (1, 79) = 4.311, MSE =
2.809, p < 0.05] and Session x DAT1 [F (1, 79) = 4.518, MSE = 2.809, p < 0.05] interactions were
significant.

To better understand these interactions, we next examined Group and Session effects for each of
the DAT1 genotypes separately. For 9R carrier participants, there was a Session x Group
interaction [F (1, 26) = 4.101, MSE = 2.304, p = 0.053] that did not quite reach significance, but
no significant main effects. This interaction for 9R carriers resulted due to a significant ON-OFF
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effect for PD patients but not controls (F < 1), with PD patients performing significantly more
poorly ON relative to OFF medication [F (1, 13) = 6.250, MSE = 2.286, p < 0.05]. For 10R/10R
participants, there was only a significant main effect of Group [F (1, 53) = 5.844, MSE = 7.268, p
< 0.025] with controls outperforming PD patients.

In sum, we see overdose effects in the 9R carrier PD group and poorer performance in 10R/10R
PD patients on medication compared to 10R/10R Controls.
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Table 3.1: Final study-immediate recall, encoding scores, and weighted recall scores for PD
patients and controls separated by DAT1 genotype
PD
Control
10R/10R
9R
10R/10R
9R
n
29
14
26
14
Final Recall
7.45 (0.41)
7.14 (0.78)
9.73 (0.44)
8.14 (0.91)
(ON)
Final Recall
7.93 (0.42)
7.71 (0.79)
9.65 (0.53)
8.14 (0.69)
(OFF)
Encoding (ON)
5.24 (0.41)
4.43 (0.55)
6.81 (0.38)
5.71 (0.70)
Encoding (OFF) 5.00 (0.43)
5.86 (0.75)
5.92 (0.50)
5.50 (0.63)
Weighted Recall 1.14 (0.05)
1.22 (0.15)
1.08 (0.03)
1.03 (0.06)
(ON)
Weighted Recall 0.97 (0.05)
1.03 (0.09)
1.16 (0.07)
1.08 (0.04)
(OFF)
All values reported are group means (SEM). First trial values correspond to the mean number of
items recalled by each group in the first study-immediate recall trial. Final recall values correspond
to the mean number of items recalled by each group in the final study-immediate recall trial.
Encoding scores were calculated for each participant by subtracting the first recall score from the
final recall score. Weighted recall scores were calculated by dividing the number of items recalled
after a 30-minute delay by the number of items recalled during the final study-immediate recall
trial. 10R/10R groups are composed of those who were homozygous for the 10R DAT1 VNTR
allele. 9R groups are composed of those who were heterozygous for the 9R DAT1 VNTR allele.
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Figure 3.1. Encoding Scores. Mean encoding scores (± SEM) during the AFLT for PD patients
and controls, on and off medication, separated into 9R carriers (n(PD) = 14; n(CTRL) = 14) and
10R/10R homozygotes (n(PD) = 26; n(CTRL) = 29) of the DAT1 40-bp VNTR polymorphism. A
single asterisk represents p < 0.05.

3.2 Recall Phase
We examined recall performance in the AFLT in a 2x2x2 mixed ANOVA with group (PD vs.
Control) and DAT1 genotype (DAT1 10R/10R vs. 9R carriers) as between-subject factors and
Session (ON vs. OFF) as the within-subject variable (Table 3.1; Figure 3.2). There was no main
effect of Group or DAT1. There was a significant Session x Group interaction [F (1, 79) = 6.737,
MSE = 0.085, p < 0.025]. Exploring this interaction further, in PD patients, we found a significant
main effect of Session [F (1, 41) = 5.411, MSE = 0.119, p = 0.025], reflecting better recall
performance when on relative to off medication with no effect of Session in controls [F (1, 38) =
1.539, MSE = 0.058, p > 0.20].
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In summary, we found that the administration of dopamine replacement medication improved
recall scores in all PD patients. There were no differential effects related to DAT1 genotype. There
were no differences in performance in the control participants based on Session, as expected given
that they did not receive dopaminergic therapy nor with respect to DAT1 genotype.
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R
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Figure 3.2. Recall Scores. Mean recall scores (± SEM) during the AFLT for PD patients and
controls, on and off medication, separated into 9R carriers (n(PD) = 14; n(CTRL) = 14) and 10R/10R
homozygotes (n(PD) = 26; n(CTRL) = 29) of the DAT 40-bp VNTR polymorphism. A double asterisk
represents p < 0.01. A single asterisk represents p < 0.05.

4.0 Discussion
4.1 Summary of Results
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We investigated the impact of DAT1 polymorphisms on encoding and retrieval in healthy, elderly
controls as well as in PD patients. We further explored the effect of dopaminergic therapy on
performance in our PD patients. With respect to encoding, we found no main effects of DAT1
polymorphisms overall or in either group. In 9R carriers, however, PD patients had lower encoding
scores on, relative to off, medication, though no ON-OFF effect was noted in 10R/10R
homozygotes. Finally, we also found that 10R/10R controls outperformed 10R/10R PD patients,
though 9R PD patients performed statistically equivalently to 9R controls.

Turning to our measure of retrieval, we found that DAT1 polymorphisms did not yield main effects
overall, or in either group, and this variable did not interact Group or Session. We found that the
administration of dopaminergic medication enhanced memory retrieval in PD patients, though
there was no effect of Session in the control group.

4.2 Memory Encoding and Retrieval in PD
This study is only the third designed to investigate explicit memory encoding and retrieval
processes separately in PD patients, both on and off dopaminergic therapy. Performance on each
study-immediate recall trial reflected the combined influences of encoding and retrieval from longterm memory, as well as of immediate or working memory processes. However, the number of
items transferred to long-term memory was expected to systematically increase across studyimmediate recall trials, with less clearly predictable effects on other processes. Consequently,
subtracting performance in the final from the first stimulus-recall trial provided a less confounded
estimate of encoding or learning (Vakil et al., 1998, 2010; Mitrushina, et al., 2005; Vakil &
Blachstein, 1993; Woodard et al, 1999; Crawford et al., 1989). Conversely, by weighting delayed
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recall performance relative to the number of items recalled on the final study-immediate recall
condition, we could assess retrieval processes, discounting differences in encoding ability across
participants (MacDonald et al., 2013; Wixted and Ebbesen, 1991).

Our findings are essentially in line with those of both previous studies, obtaining poorer encoding
scores on than off medication for 9R PD carriers and improved recall performance for PD patients,
irrespective of genotype, on relative to off medication. MacDonald and colleagues (2013) and
Grogan and colleagues (2015) similarly found that encoding in PD is superior at baseline and is
worsened by dopaminergic medication. In contrast, retrieval was found to be impaired in the OFF
state and was improved by dopamine supplementation. This pattern of findings is easily explained
relating the different brain regions that are implicated in encoding and retrieval to known PD
pathophysiology.

4.3 Interpretation of Memory Encoding Results
Encoding is consistently shown to recruit and depend upon VTA-innervated brain regions. Early
studies in patients with temporal lobectomies revealed an inability to encode new explicit
information (Milner, 1968, 1972; Scoville and Milner, 1957). Using neuroimaging techniques,
explicit memory encoding has also been shown to preferentially engage the VTA-innervated
medial temporal structures, such as the hippocampus (Schrager et al., 2008). An influential model
proposed by Lisman and Grace (2005) describes a novelty-dependent loop responsible for longterm memory encoding which includes hippocampus, subiculum, pallidum, VS, and VTA. The
hippocampus is described as the gate to this loop. It detects novel information and sends a
downstream signal through the subiculum and pallidum to VS, where connections to the VTA

46
arise, eliciting dopamine release from the VTA to the hippocampus. Dopamine release from the
VTA to the hippocampus is postulated to facilitate memory encoding. Hippocampus activity has
been noted during the presentation of novel stimuli and during memory studies of intentional
encoding using a variety neuroimaging as well as molecular techniques, including single-unit
recordings (Fyhn et al., 2002) PET (Tulving et al., 1996), fMRI (Strange and Dolan, 2001;
Yamaguchi et al., 2004; Spaniol et al., 2009) and c-Fos quantification (Jenkins et al., 2004).

Another brain region that receives dopaminergic innervation from VTA and has been implicated
in learning and encoding is the OFC. OFC is bi-directionally connected to medial temporal regions
such as the hippocampus (Barbas, 1993; Barbas and Blatt, 1995; Catenoix et al., 2005; Cavada et
al., 2000). OFC activity is elicited during the presentation of novel visual stimuli in non-human
primates (Rolls et al., 2005). OFC activity is also correlated with subsequent successful recall
performance (Frey and Petrides, 2003). Given that OFC has been found previously to be activated
during the presentation of deviant visual stimuli (Petrides et al., 2002), OFC may be implicated in
the encoding process of the AFLT. OFC may be engaged during the presentation of a symbol that
was incorrectly recalled during a previous recall phase because the presented symbol will appear
deviant relative to the participant’s incorrect memory of it. Therefore, deficient functioning of
VTA-innervated OFC may contribute to deficient encoding.

In addition to its proposed role in the novelty-dependent encoding loop proposed by Lisman and
Grace (2005), VS, another VTA-innervated brain region, seems to be implicated in learning and
memory encoding (Atallah et al., 2007; Hiebert et al., 2014; MacDonald et al., 2013; Spaniol et
al., 2009). Early theories suggested that VS is specialized for reward learning and processing
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(Camara et al., 2010; Cools et al., 2002; Delgado et al., 2000, 2007; Knutson and Cooper, 2005;
O’Doherty, 2004; Preuschoff et al., 2006; Sesack and Grace, 2010). However, a role for VS in
learning situations where no reward, punishment, or even feedback is present has been described
in many recent studies (Feigin et al., 2003; Ghiladri et al., 2007; MacDonald et al., 2011; Reiss et
al., 2005; Seo et al., 2010; Shohamy et al., 2006; Tremblay et al., 2010).

Characteristic of a region implicated in learning and encoding, VS activity noted using
neuroimaging is greatest early in a task, when rules and strategies are being acquired (Seger, 2006,
2010; Delgado 2005; Filoteo et al., 2005) and decreases as performance asymptotes (Reiss et al.,
2005; Hiebert et al., 2014). Once learning is established, VS activity only peaks after salient events
occur, such as the reception of unexpected rewards (Bray et al., 2007; Breiter et al., 2001;
Rodriguez et al., 2006; Ullsperger et al., 2003; Hampton et al., 2007) or negative feedback after
errors (Simoes-Franklin et al., 2010).

Though the examples in the preceding paragraph relate to situations in which encoding occurs
implicitly or unconsciously, VS was identified as a region in a meta-analysis of explicit memory
encoding (Spaniol et al., 2009). Further, Goldenberg and colleagues (1999) documented an
inability to intentionally learn new verbal material in a patient following a focal, left nucleus
accumbens (i.e., VS) bleed. In contrast, this patient performed normally on measures that
demanded retrieval of previously-learned verbal information, or tests of divided and shifting
attention, working memory, language, as well as of encoding and retrieval of non-verbal
information. Finally, Mizuta and Motomura (2006) investigated explicit word list learning in three
patients with infarcts owing to left recurrent artery of Heubner (RAH) occlusions—the artery that
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specifically and exclusively supplies VS—documented during neurosurgical intervention for
anterior communicating artery (AComm) aneurysms, relative to two patients with right RAH
occlusions and three patients treated for AComm aneurysms without RAH impairment or
consequent VS infarction. Patients with left but not right VS infarcts were specifically impaired in
word list learning. Taken together, these results seem to implicate VS in explicitly learning new
information, with left VS lateralized for verbal materials.

The VTA is relatively spared in PD, particularly at early stages of disease (Kish et al., 1988).
Administration of exogenous dopamine, titrated to motor symptoms mediated by the significantly
dopamine-depleted DS, reliably impairs functions performed by VTA-innervated brain regions,
such as VS, limbic, and prefrontal cortical regions, through dopamine overdose (Gotham, 1988;
Cools et al., 2006; MacDonald and Monchi, 2011). This includes explicit memory encoding
(Chiaravalloti et al., 2014; Ellfolk et al., 2013; Knoke et al., 1998; MacDonald et al., 2013; Grogan
et al., 2015). In addition to increased dopamine concentrations in VTA-innervated regions relative
to DS, particular cytoarchitectonic aspects of VS are likely to predispose this region to disruption
from dopamine overdose. VS MSNs are smaller relative to other MSN populations, have fewer
dendrites and spines, and have sparser dopaminergic input than DS (Wickens et al., 2007). As
such, receptor stimulation in VS is slower and more sensitive to dopaminergic input intensity
(Wickens et al., 2007). Indeed, VS MSNs show graded, incremental, and more finely-tuned
responses affected to a greater degree by the intensities or frequencies of dopamine impulses than
DS (Zhang et al., 2009). Additionally, VS has a lower DAT concentration than DS, which, through
decreased synaptic clearance, results in a longer duration response to dopamine stimulation
(Wickens et al., 2007). Given these cytoarchitectonic features—independent of the fact that it
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receives more ample dopaminergic supply at baseline due to its innervation from spared VTA—
VS seems more susceptible to exogenous dopamine overdose and disruption of its function than
DS.

4.4 Interpretation of Memory Retrieval Results
Explicit retrieval processes (e.g., recall and recognition memory processes) have been less well
researched, but seem to implicate more distributed brain regions, including DS and cortical regions
to which DS is reciprocally connected, in addition to medial temporal structures (Spaniol et al.,
2009). Frontal lobe lesions, particularly in dlPFC (Gershberg and Shimamura, 1995; Eslinger and
Grattan, 1994; Stuss et al., 1994) impair free recall, and these brain regions as well as a dorsal
frontoparietal network (Kragel and Polyn, 2013) are engaged preferentially using neuroimaging
during free recall and recognition memory testing. A meta-analysis of 30 neuroimaging studies
investigating retrieval in a recognition memory performance revealed large clusters of preferential
activation in DS, dorsal frontal regions such as dlPFC, and other cortical partners of DS, including
frontal eye fields and motor cortices (Spaniol et al., 2009). In other studies, DS is preferentially
activated in neuroimaging studies when recognizing previously-presented items in an episodic
recognition test (Kim, 2010) as well as during remembering of category membership (Seger et al.,
2010; Helie et al., 2010).

In addition to explicit memory retrieval tests, DS is implicated in implicit forms of remembering.
DS is engaged when performing previously-learned motor sequences relative to the performance
of random motor sequences (Reiss et al., 2005). DS is instrumental in navigating the Morris Water
Maze (MWM)—a task that requires the unconscious retrieval and application of previously-
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learned information (Miranda et al., 2006; Miyoshi et al., 2012). Increased oxidative metabolism,
an indirect measure of cellular activity, is observed in DS in experimental animals performing
tasks that require retrieval of previously-learned spatial information (Mendez-Couz et al., 2015;
Miranda et al., 2006; Miyoshi et al., 2012). In humans, participants deemed to be more accurate
spatial navigators have been shown to have higher hippocampal and caudate activations when
following a well-learned route in a familiar environment (Hartley et al., 2003). These findings
support the notion that DS plays a role in tasks that require the retrieval of previously-learned
information both explicitly and implicitly.

DS is most often implicated in decision making and response or action selection (Grahn et al.,
2008; Hiebert et al., 2014). Studies of DS lesions in humans and non-human primates have shown
deficits in shifting attention between stimuli, especially away from more salient ones (Benke et
al., 2003; Cools et al., 2003, 2010; Thoma et al., 2008), in flexibly altering decision-making
strategies or response sets (Benke et al., 2003; Cameron et al., 2010; Ell et al., 2006; Grahn et al.,
2008; Leber et al., 2008; Yehene et al., 2008), suppressing more automatic responses (Benke et
al., 2003; Cameron et al., 2010; MacDonald et al., 2011; White, 2009; Robertson et al., 2015), and
in updating goals when the parameters for decisions have changed (Grahn et al., 2008; Hazy et al.,
2006; Vakil et al., 2004). Reviewing this extensive literature, DS is implicated in flexible decisionmaking and selecting, particularly in ambiguous or high-competition contexts (Ali et al. 2010;
Grinband et al., 2006; MacDonald et al., 2011; Monchi et al., 2001, 2006; Robertson et al., 2015
Rogers et al., 2000; van Schouwenburg et al., 2010). DS promotes selection of responses or actions
in the motor system and of sensory stimuli via attentional systems (Ali et al., 2010, Leung et al.,
2000, Pardo et al., 1990, Pinel et al., 2004, Peterson et al., 1999, 2002; MacDonald et al., 2011).
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We speculate that analogously, DS’s role in retrieval is to facilitate selection among internally
generated stimuli.

DS is seriously dopamine restricted in PD in the OFF state, even at early stages of disease.
Consequently, functions mediated by DS, such as movements and cognitions, are impaired when
PD patients are tested off dopaminergic therapy. Functional neuroimaging has also revealed that
cortical networks implicating DS are dysfunctional in PD patients in the OFF state (MacDonald
and Monchi, 2011). Consistent with this literature, delayed recall in the AFLT was impaired in PD
patients off medication relative to performance of healthy controls (MacDonald et al., 2013).
Functions performed by DS and by its cortical partners are consistently improved by dopaminergic
supplementation. In line with this, we found that in PD patients, recall after delay, weighted
relative to number of items recalled in the final study-immediate recall phase, was improved by
dopaminergic therapy.

The cytoarchitectonics of DS are quite different than those of VS. As such, it is expected that
dopamine replacement medication will affect DS in a different manner than is expected in VS. DS
is supplied by very dense dopamine inputs from the SN. This high density of dopamine inputs and
the numerous dendrites and spines on DS MSNs (Wickens et al., 2007) cause rapid and maximal
responses in DS through a wide range of SN firing frequencies and intensities (Wickens et al.,
2007; Zhang et al., 2009). Further, DS is invested with high concentrations of DAT1, resulting in
dopamine being rapidly cleared after release from presynaptic terminals. This results in short
periods of dopaminergic stimulation for DS MSNs (Wickens et al., 2007). When all the above is
considered, dopaminergic stimulation in DS is precisely-timed, brief, and seemingly binary
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because maximal responding occurs over wide ranges of stimulation. DS seems attuned for rapid,
flexible, and more absolute responding that would be advantageous for a brain region implicated
in deciding between alternatives. These characteristics also suggest that DS is more likely to
benefit from exogenous dopamine, as finely-tuned or graded responses are not observed, and this
region seems less likely to experience dopamine overdose.

4.5 Relevance of Current Study to Memory Function in PD
The current study, along with those that have employed a similar approach, provide a framework
for beginning to understand the significant inconsistency that arises in the PD memory literature
(Chiaravalloti et al., 2014; Ellfolk et al., 2013; Knoke et al., 1998; Pirogovsky-Turk et al., 2015;
Ellfolk et al., 2012; Higginson et al., 2005; Ibarretxe-Bilbai et al., 2011; Vingerhoets et al., 2005).
Most previous investigations of memory have tested PD patients either on or off dopaminergic
therapy, not both, obtaining memory measures influenced by combined encoding and retrieval
processes. Performance in these studies, therefore, reflects the summed effects, in unknown
proportions, of a) some deficient and b) other spared memory processes in PD, as well as of c)
medication-induced improvements in some operations and d) impairments in others. To elaborate,
accounting for the considerable variability in the PD memory literature, even small methodological
changes across studies could greatly affect the estimates of memory that are obtained. Procedures
that emphasize encoding will have contrary effects on performance to methods that accentuate
retrieval processes. Adding further to the inconsistency, dopaminergic therapy exerts opposite
effects on encoding and retrieval processes, as shown in our study.

4.6 DAT1 Effects on Memory Function in PD
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The most novel aspect of our study was that we investigated the impact of differences in DAT1
polymorphisms on performance in PD. Our study constitutes the first to investigate the effect of
9R versus 10R/10R polymorphisms in the DAT1 gene on explicit memory encoding and retrieval,
in healthy elderly controls compared to PD patients.

4.6.1 Encoding Effects
DAT1 controls clearance and re-uptake of synaptic and extrasynaptic dopamine, particularly in
striatum and hippocampus. Recent meta-analyses have concluded that expression of DAT1 9R
allele is higher than the 10R/10R homozygotes (Costa et al., 2011; Faraone et al., 2014), despite
previous studies that have concluded the opposite (Jacobsen et al., 2000; van de Giessen et al.,
2009; van Dyck et al., 2005). As such, 9R carriers are predicted to have lower concentrations of
synaptic and extra-synaptic DA compared to 10R/10R participants at baseline. Lower baseline
dopamine concentrations were hypothesized to yield higher signal-to-noise ratio, with more impact
of teaching signals in the form of event-related, phasic, and pulsatile dopamine bursts relative to
tonic or basal dopamine levels. Consequently, we expected 9R carriers to evidence improved
encoding relative to 10R/10R participants.

There were no main effects of DAT1 genotype on encoding overall or in either group separately.
Though we predicted differences on the basis of DAT1 genotype, failure to find significant
differences was not inconsistent with the literature in healthy participants. To this point, standard
behavioural measures have not clearly revealed differences in performance based on DAT1
genotypes (Congdon et al., 2009; Eisenegger et al., 2013; Garcia-Garcia et al., 2010; Kasparbauer
et al., 2015; Schott et al., 2006). Neuroimaging measures appear to be more sensitive to these
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differences, however. In healthy participants, larger activations are elicited in the midbrain
dopaminergic reward system in 9R carriers compared to 10R/10R homozygotes (Dreher et al.,
2009; Forbes et al., 2009; Hariri et al., 2006). Further, enhanced activity in VS, inferior PFC, and
anterior cingulate cortex have been noted in 9R carrier healthy participants during successful
encoding of list items (Schott et al., 2006). In addition to the possibility that our behavioural
measures were too insensitive to detect differences in encoding performance across genotype that
have been noted previously in terms of neural activity using functional neuroimaging, our current
experiment was underpowered with 28 9R carriers and 55 10R/10R homozygotes overall (14 9R
carrier PD patients, 14 9R carrier controls, 29 10R/10R PD patients, and 26 10R/10R controls).

Contrasting PD and Control groups on encoding for each genotype independently, we found poorer
performance for PD patients relative to controls for the 10R/10R genotype only. Taken at face
value, this could suggest that for 10R/10R PD homozygotes, higher basal dopamine decreased
efficiency of event or reward-related pulsatile dopamine to achieve the necessary phasic-to-basal
ratio to produce downstream signaling. Due to even minor dopamine depletion in VTA-innervated
regions, PDs could have been more affected than controls by the inefficiency in reaching critical
signal-to-noise differences, through generation of sufficiently large phasic dopamine bursts
relative to the higher basal dopamine levels in the 10R/10R homozygotes. Previous research
suggests that exceeding a given signal-to-noise (i.e., phasic-to-basal dopamine) threshold triggers
activation of D1 receptor neurons and learning (Frank, 2005; Kerr and Wickens, 2001; Kravitz et
al., 2012; Reynolds et al., 2001; Shen et al., 2008; Wickens et al., 2003). Further, PD lessens DAT1
levels further (Booij et al., 1997), potentially further increasing tonic, basal dopamine in 10R/10R
PD patients in the OFF as well as in the ON dopaminergic therapy state. Finally, repeated and
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chronic exposure to dopaminergic therapy could yield receptor changes that exacerbate these
inefficiencies (Aquino et al., 2015).

The above interpretation of the finding that encoding was less effective in PD 10R/10R relative to
control 10R/10R is constrained by the fact that 9R and 10R/10R PDs did not differ in encoding
performance. Further, this differential effect for PD 10R/10R and PD 9R carriers relative to their
respective control groups must be viewed in the light of the fact that we obtained more 10R/10R
homozygotes than 9R allele carriers in this study. In this way, power to detect statistical differences
for contrasts involving the former group was increased compared to those including the latter
group.

Based on previous research (MacDonald et al., 2013; Grogan et al., 2015), we expected encoding
to be impaired in PD patients tested on relative to off dopaminergic therapy. This is due to the fact
that encoding is mediated by brain structures that receive dopamine supply from the relativelyspared VTA. These brain regions are sensitive to overdose from exogenous dopamine therapy that
is titrated to DS-depletion levels and overdose has been reliably shown in many functions mediated
by VTA-innervated brain regions (Cools et al., 2006; MacDonald & Monchi 2011). Further, we
predicted that 9R PD patients will be more sensitive to overdose from exogenous dopamine and,
therefore, will have greatest impairment for on relative to off performance. 9R PD patients have
lower tonic dopamine levels due to increased DAT1 expression and consequently more rapid
synaptic clearance and reuptake of dopamine. This results in a more optimized signal-to-noise
ratio. When dopamine is delivered in a non-physiological way, it is expected that DAT1 reuptake
mechanisms are exceeded, resulting in higher tonic dopamine levels and a decreased signal-to-
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noise ratio to which these 9R individuals are unaccustomed. For the ON 10R/10R PD, exogenous
dopamine is expected to have lesser detrimental effect on learning performance given that larger
fluctuations in basal dopamine are experienced and tolerated by these individuals in their baseline
state. That is, in the context of already elevated tonic dopamine levels at the synapse in this
10R/10R PD group in the off state, dopamine supplementation will alter the relative magnitude of
the phasic-to-tonic dopamine ratio (i.e., signal-to-noise) to a lesser extent. Potentially higher phasic
dopamine responses will actually occur in the 10R/10R PD group in the ON state compensating
for any changes in tonic dopamine, with lesser effect ultimately on downstream signaling. Effects
bolstering these expectations were seen in a study examining the effects of DAT1 genotype on
learning about the prosociality of others in a healthy control group (Eisenegger et al., 2013). That
is, in line with these predictions, in a previous study, healthy 9R carriers who were given L-dopa
were less able to learn about the playing style of a partner in an interactive experimental task and
could not, therefore, adopt an adaptive strategy to maximize their winnings (Eisenegger et al.,
2013).

In line with our expectations, 9R carrier PD patients had lower encoding scores on medication
relative to off medication. This group is expected to experience a greater perturbation on their
signal-to-noise ratio produced by phasic relative to tonic dopamine levels at the synapse. However,
no ON-OFF differences in encoding performance occurred for our 10R/10R homozygotes. This is
the first study to investigate the effect DAT1 and exogenous dopamine on a cognitive function
mediated by a VTA-innervated brain region. Previous studies look only a mixed genotype group
effects. We speculate that overdose effects were absent in the 10R/10R PD group because the
relative increase in synaptic dopamine concentrations from baseline to ON medication state would
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be of a smaller magnitude in this group than in the 9R group. Experience with and tolerance to
higher tonic dopamine levels at baseline in this group might have been protective to overdose
effects. However, again it is important to consider that these investigations were performed in
small numbers of participants and that the reliability of this pattern of findings will be enhanced
by testing with larger sample sizes.

4.6.2 Retrieval Effects
For recall, we speculated that DAT1 9R carriers might reveal superior performance as well, due to
a more optimized signal-to-noise ratio in selecting among internal stimuli to produce recall
responses. However, retrieval has been shown to implicate DS and DS-involving cortical networks
(Spaniol et al., 2009) and the cytoarchitectonics of DS adapt it to easily achieve maximal firing or
responsivity, for very brief durations (Wickens et al., 2007), based on a broad range of SN firing
frequencies and intensities (Wickens et al., 2007; Zhang et al., 2009). In this way, differences in
baseline or tonic dopamine levels in DS were speculated to potentially have lesser impact on
success of event-related, phasic dopamine to achieve successful D1 and D2 receptor stimulation
and signal transduction. Decreased effect of these phasic-to-tonic ratios across participants, on
activity levels in DS (Zhang et al., 2009) ultimately translates to less influence on activation in
DS’s cortical partners via facilitation of the direct pathway and inhibition of the indirect pathway.
In this way, we expected that 9R and 10R/10R genotypic backgrounds might have less influence
on recall performance than we expected for encoding. Recall implicates broader brain regions
including DS and cortical networks involving DS (Spaniol et al., 2009). In PD, DS is significantly
dopamine depleted even at the earliest stages of disease, and motor and cognitive functions
mediated by DS are impaired (Cools, 2006; Cools and D’Esposito, 2011; Cools et al., 2001, 2003;

58
Frank, 2005; Frank et al., 2004; Hood et al., 2007; Lewis et al., 2005; MacDonald and Monchi,
2011; MacDonald et al., 2011; Moustafa et al., 2008a, 2008b; Shook et al., 2005; Slaboz et al.,
2006; Tremblay et al., 2010). Consequently, we expected PD patients to perform more poorly than
controls regardless of genotype, and further that all PD patients would recall more items in the on
than off dopamine state. Finally, it seemed less likely that exogenous dopamine therapy would
have differential effects on PD patients based on DAT1 genotypic differences.

Indeed, we found no main effect of DAT1 genotype on recall performance overall or within each
of our groups. Further, DAT1 genotype did not interact significantly with Group or with
Medication Session. As predicted, we found that PD patients recall was improved on dopaminergic
medication relative to off, replicating previous research (MacDonald et al., 2013; Grogan et al.,
2015, but see Bronnick et al., 2011). This pattern is entirely predictable because DS is severely
dopamine depleted in PD.

4.7 Limitations of the Current Study
We acknowledge a number of limitations of the current study. Foremost, the interpretation of our
findings related to effects of DAT1 polymorphisms and dopaminergic therapy on encoding and
retrieval remains speculative given that the present study is merely behavioural. Without
integrating functional neuroimaging into our protocols or examining these processes in patients
with focal lesions, our explanations remain provisional. Going forward, we will confirm our
interpretations by coupling our behavioural paradigm in PD patients and healthy controls, on and
off dopaminergic therapy using functional neuroimaging.
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Further, despite promising and predicted patterns, our study remains underpowered due to small
sample sizes, particularly in our 9R carrier participants. This led to differences in age and MOCA
in our 10R/10R PD group relative to its control group, which could potentially influence our
findings. Critically, our main finding related to DAT1 polymorphisms resulted from a withinsubject comparison, which would not be influenced by these demographic group differences. The
reliability and generalizability of our results are also questioned by this small sample size.
Recruitment is currently underway to address this issue and boost our statistical power.

Lastly, we recognize the limitations of examining polymorphisms in a single gene influencing
dopamine regulation in the brain. This is an ongoing project, and we plan to investigate the effects
of additional dopaminergic gene polymorphism such as in COMT, the D2 receptor, and dopamineand cAMP-regulated phosphoprotein. These polymorphisms will affect dopamine clearance in the
PFC, hippocampus, as well as in the direct and indirect signaling pathways. The inclusion of these
polymorphisms will allow us to investigate interactive effects, rather than assessing the effects of
a single gene polymorphism in isolation. Several studies of the effects of dopaminergic
polymorphisms have found interactive effects or have shown that it is necessary to control for
some polymorphisms on others (e.g., Cockburn et al., 2014; Nikolova et al., 2011; Smith et al.,
2013; Yacubian et al., 2007).

4.8 Conclusion
We found that dopaminergic therapy had differential effects on explicit memory encoding and
retrieval in PD patients relative to healthy age-matched controls, essentially replicating findings
of the only two previous studies that have examined memory in PD in this manner (MacDonald et
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al., 2013; Grogan et al., 2015). We found that dopaminergic therapy worsened encoding, for a
subset of our PD patients based on genotype, and improved retrieval in PD. These results
contribute to a greater understanding of memory impairments in PD, helping to clarify significant
inconsistencies that occur in this literature to date.

We further explored the effect of DAT1 genotypic variations on memory performance in healthy,
elderly volunteers and in PD patients. At a behavioural level, there were no differences in encoding
or recall performance based on DAT1 genotype within the PD or control groups. Only, 9R PD
patients experienced overdose effects with poorer encoding on relative to off dopaminergic
therapy. This was explained on the basis of differences in phasic-to-tonic dopamine ratio for this
group compared to 10R/10R homozygotes. Understanding how genetic background influences
cognition and response to dopaminergic therapy in PD could lead to more tailored treatment
regimens that attempt to remediate DS-mediated motor and cognitive functions while minimizing
detrimental effects on other cognitive functions. Caution, however, should be exercised in these
interpretations until patterns can be explored in a larger dataset. Future studies will aim to correlate
our findings with regional brain activation using neuroimaging to confirm our interpretation of our
findings.
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